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ABSTRACT OF THE DISSERTATION 
 
Biomaterials for Modulating VEGF-induced Angiogenesis through Specific Integrin Binding 
by 
 
Shuoran Li 
Doctor of Philosophy in Chemical Engineering 
University of California, Los Angeles, 2017 
Professor Tatiana Segura, Chair 
 
The objective of this research was to study and engineer the signals that promote angiogenesis 
in the wound healing process.  These signals include but are not limited to growth factors and 
integrin ligands. Extracellular matrix (ECM) molecules such as fibronectin, growth factors such 
as VEGF (vascular endothelial growth factors), and their receptors have been shown to be key 
regulators of angiogenesis and neovascularization, with embryos lacking these genes dying due 
to defects in angiogenesis1, 2. Currently, efforts to optimize angiogenic biomaterials have been 
focused dominantly on (1) controlling angiogenic factor release or presentation (the binding 
methods) and (2) modulating the material’s bulk physical properties and integrin ligand density.  
The controlled growth factor release and presentations have also been thoroughly studied. For 
example, the design of therapeutic angiogenic materials to treat cardiovascular diseases, such 
as deficient blood supply to the heart, limbs, and brain, has primarily been driven by the delivery 
of growth factors within a scaffold. Out of the entire library of growth factors, we selected VEGF 
as our model molecule, since it has been described as the master regulator of angiogenesis. 
Methods such as repeated low dosing of soluble VEGF, protease-responsive VEGF 
nanocapsules and covalently-bound VEGF in hydrogels have shown to promote regeneration of 
 iii 
functional healthy vessels. However, there are still many questions remaining to be answered in 
the field of growth factors. My dissertation focuses on answering three major ones: (1) How can 
we monitor the delivery of a growth factor in a signal-response cargo system, such as protease-
degradable VEGF nanocapules? (2) Is there another presentation form of VEGF that can 
effectively promote therapeutic wound healing? (3) Besides the presentation method, does the 
distribution of growth factors across a substrate or within a matrix affect cellular response? Can 
we develop a screening system for it?  
Aside from growth factors, integrins also play an important role in the process of angiogenesis. 
However, even though adhesive ligands that promote integrin binding are generally 
incorporated within therapeutic angiogenic materials, the subsequent cell-material interactions 
have not been explored as an angiogenic signal. As there are many different types of integrin 
pairs which exist in nature, we still do not fully understand the function of each one of them in 
the process of angiogenesis. In this dissertation, I hope to answer the question: Aside from bulk 
physical properties and integrin ligand density, does the integrin-specific design of biomaterials 
play a role in biomaterial-mediated angiogenesis? If so, then what type of role? I deeply 
investigated how integrins affect vessel morphogenesis and therapeutic outcomes using both 
the subcutaneous mouse and ischemic stroke mouse models. We discovered that integrin 
specificity can significantly impact the vascular outcomes. This work shows for the first time that 
precisely controlled integrin activation from a biomaterial can be harnessed to direct therapeutic 
vessel regeneration and reduce VEGF induced vascular permeability in vivo. 
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Chapter 1  
Overview of dissertation and specific aims 
 
 
1.1 Motivation and Objectives 
The design of therapeutic angiogenic materials to treat cardiovascular diseases, such as 
deficient blood supply to the heart, limbs, and brain, has primarily been driven by the delivery of 
angiogenic factors within a scaffold. Fibronectin, VEGF and their receptors have been shown to 
be key regulators of angiogenesis and neovascularization, with embryos lacking these genes, 
resulting in lethality due to defects in angiogenesis1, 2. Optimization of these materials has been 
focused dominantly on controlling angiogenic factor release or presentation and modulating bulk 
physical properties.The objective of this research was to understand and engineer the signals 
that promote wound healing.  These signals include but not limited to growth factors and integrin 
ligands.  
To study the effects from growth factors, we first wanted to evaluate the current 
nanocapsule technology for growth factor delivery and develop techniques to help us better 
visualize nanocapsules and moniter the degradation process. In our study, we used VEGF-core 
nanocapsules with different protease-degradability to test a portable computational imaging 
system. Second, we would also like to investigate how different formats of growth factor affects 
vessel regeneration process. In our study, we mainly investigated VEGF (Vascular Endothelial 
Growth Factor) in a cluster format. We would like to understand how different presentations of 
growth factors (not limited to soluble, electrostatically-bound, covalently-bound) actually affect 
therapeutic outcomes on diseased animal model. We hypothesized that this would help us 
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design more efficient growth factor delivery methods for therapeutic purposes. Third, we hoped 
to develop a universal system to look at the distribution effects of growth factors.  We 
hypothesized that by generating a nano-patterned surface, the pathway activation from different 
distribution of growth factors can be studied. We hypothesized that even with the identical 
amount of growth factor dosage, the difference in distribution of growth factors can greatly 
affects cellular response. 
For integrin activation studies, the objective is to understand how integrin activation 
guides endothelial cell fate.Although adhesive ligands that promote integrin binding are 
generally incorporated within therapeutic angiogenic materials, the subsequent cell-material 
interaction has not been explored as an angiogenic signal. It has been known that integrin 
activation can guide MSC (Mesenchymal Stem Cell) differentiation, yet no study has been done 
to really understand how the different integrin activation affect vessel regeneration. We 
hypothesized that materials with different integrin activation affects HUVEC sprouting and 
branching, which leads to different vessel morphogenesis and functionality.  
 
1.2 Specific Aims  
1.2.1 Specific Aim 1 (Chapter 3) 
This aim developed a portable imager which detects nanocapsule degradation real-time. 
The VEGF nanocapules with different protease-degradability were utilized as template in this 
study. Samples treated with protease at different time points were tested. Samples were also 
real-time imaged to monitor real-time degradation.  
Hypothesis 1: Nano-lens based computational microscopy can be utilized as an effective 
tool to monitor nanocapsule degradation, such as protein-core VEGF nanocapsules. 
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1.2.2 Specific Aim 2 (Chapter 4) 
This aim investigated the effects of specific integrin activation on angiogenesis. A 3D 
fibin gel sprouting assay was carried out to study HUVEC sprouting and branchingin vitro. Then 
a modified matrigel assay was performed on mouse model to look at neo-vessel infiltration and 
neo-vessel morphology. Later, an ischemic stroke mouse model was also utilized to study the 
neo-vessel generation and infiltration in the stroked areain vivo.  
Hypothesis 2: Integrin-specificity matrix can be utilized to as a morphogenic cue in 
guiding endothelial cell responses both in vitro and in vivo. Specific integrin activation could 
induce the generation of healthy and non-leaky vessels.  
 
1.2.3 Specific Aim 3 (Chapter 5) 
This aim utilized the cluster format of VEGF to treat diabetic mouse cutaneous wounds. 
The wound closure percentage, epithelial layer thickness, endothelial cell and pericyte 
infiltration percentage were all studied.  
Hypothesis 3: Clustered VEGF can promote diabetic cutaneous wound healing.  
 
1.2.4 Specific Aim 4 (Chapter 6) 
This aim designed a large nano-patterned surface to study the distribution effects of 
VEGF. VEGF was immobilized to nano-islands on ultra-flat glass surface which is about 600-
700nm in diameter.  Homogenous immobilized VEGF was used as control. VEGFR-2 activation 
study was performed using Western Blots and qPCR. HUVECs were later directly seeded on 
the nano-patterned surface to look at cell attachment and spreading. 
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Hypothesis 4: The discontinuous distribution of VEGF immobilization on nano-patterned 
surfaces will result in a distinct VR-2 phosphorylation pattern, downstream signal, EC 
morphology and phenotype compared with homogenous immobilized VEGF. Both western blot 
analysis andPCR technique can be used to analyze the outcomes on the protein and mRNA 
expression levels.  
 
1.3 Dissertation Outline 
After this introductory Chapter, Chapter 2 will provide relevant background to the 
dissertation topic. The flow of the dissertation is illustrated in Figure 1.1. After testing the VEGF 
nanocapules degradability using computational imaging system (Chapter 3), the VEGF 
nanocapsules were incorporated into hydrogel matrix together with different types of integrin-
specific fibronectin fragments to look at the effects of integrin specificity on angiogenesis 
outcomes both in subcutaneous mouse model and stroke mouse model (Chapter 4). After 
determining the angiogenesis effects from integrin specificity, the research actually turned to 
investigate the different presentation formats of VEGF, which is the master regulator in 
angiogenesis. VEGF clusters were dosed on diabetic mouse model to study the effects of VEGF 
clusters on cutaneous wound healing (Chapter 5).  Besides looking at the angiogenesis effects 
from different growth factor presentation, the discontinuous distribution effects of growth factor 
was also studied. Here, VEGF is still used as a template. The nano-patterns with discontinuous 
VEGF immobilization was compared with homogeneous distributed VEGF to look at the 
difference in VEGFR-2 activation (Chapter 6).   
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Figure 1.1 The flow of the dissertation. 
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Chapter 2  
Introductions 
 
 
2.1 Degradable nanoparticles monitoring 
Design and synthesis of degradable nanoparticles are very important in drug delivery 
and bio-sensing fields. Although accurate assessment of nanoparticle degradation rate would 
improve the characterization and optimization of drug delivery vehicles, current methods rely on 
estimating the size of the particles at discrete points over time using e.g., electron microscopy or 
dynamic-light-scattering (DLS), among other techniques, all of which have several drawbacks 
and practical limitations. There is a significant need for a high-throughput and cost-effective 
technology to accurately monitor nanoparticle degradation as a function of time and using small 
amounts of sample. To address this need, here we present two different computational imaging 
based methods for monitoring and quantification of nanoparticle degradation. The first method is 
suitable for discrete testing, where a computational holographic microscope is designed to track 
the size changes of protease-sensitive protein-core nanoparticles following degradation, by 
periodically sampling a subset of particles mixed with proteases. In the second method, a 
sandwich assay was utilized to observe, in real-time, the change in the properties of liquid 
nanolenses that were self-assembled around degrading nanoparticles, permitting continuous 
monitoring and quantification of the degradation process. These cost-effective holographic 
imaging based techniques enable high-throughput monitoring of the degradation of any type of 
nanoparticles, using an extremely small amount of sample volume that is at least three orders of 
magnitude smaller than what is required by e.g., DLS-based techniques.   
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Over the past few decades nanotechnology has been utilized extensively in biomedical 
sciences for a variety of applications such as oncology, cardiology, wound healing, and many 
others1. Various types of nanoparticles have been designed and synthesized to deliver different 
payloads, such as drug molecules, proteins, nucleic acids to target cells or tissues2. Compared 
with bulk delivery without a carrier, utilization of nanoparticle carriers offers several advantages, 
such as drug stability, controlled release rate and also targeted delivery. A nanoparticle carrier 
is generally designed (i) to protect its cargo from in vivo degradation and external perturbations 
to its physical and bio-chemical properties and (ii) to deliver the drug at controlled dosages. 
Additionally, surface modification of nanoparticles enables specific targeting to particular cells, 
which helps in reducing cellular toxicity, especially in chemotherapy, improves systematic 
circulation time and increases retention at target sites, such as tumor3,4. It can also be utilized to 
simultaneously carry multiple drugs to the same target, such as a chemo-drug and a sensitizer5.  
To achieve controlled drug delivery, nanoparticles are often designed to be degradable6. 
An important design principle of degradable nanoparticles is that they degrade into non-toxic 
components that can be cleared by the body. Generally, such nanoparticles are designed to 
undergo degradation triggered and facilitated by the local microenvironment that is specific to 
the targeted disease. Different diseases can lead to formation of unique microenvironments at 
the cellular or tissue level, as a hallmark of the disease. For example, certain tumor 
microenvironments are characterized by elevated glutathione levels, low pH and increased 
protease activity, wounds are characterized by lower oxygen and higher protease levels, etc. 
These known features of some diseases have been exploited to develop specific nanocarriers, 
with degradation mediated by e.g., pH7,8, glutathione9, proteases, enzymes10,11, antigens12 etc. 
Another common approach is to design nanoparticles that can release drugs after degradation 
due to external perturbations such as light13, heat14,15, ultrasound, electric16 and magnetic 
fields17,18.    
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During their design and test phase, the most commonly used method for observing 
nanoparticle degradation is by correlating it with the amount of drug released14. The drug 
release is monitored by isolating the free drug molecules followed by direct quantification using 
analytical or bio-chemical techniques or by indirectly monitoring its effect. However, these 
methods can only be used for drug loaded nanoparticles undergoing degradation. In general, 
design and synthesis of biodegradable nanoparticles, without the cargo, require a direct method 
for observing and quantification of the changes in their matrix. Several techniques such as 
Raman spectroscopy19, fluorescence resonance energy transfer20, optical absorption21,22,23 and 
Magnetic Resonance Imaging (MRI)24 have been previously utilized to monitor the degradation 
process of the nanoparticle matrix. However, these methods can only be used for specific types 
of nanoparticles and are not universally applicable for any type of particle. Some of the more 
general strategies that have been used for monitoring nanoparticle degradation involve 
measurement of weight or size by using chromatography25, dynamic light scattering (DLS)14 and 
electron microscopy (EM)26. These methods can provide an estimation of the nanoparticle 
degradation process but each has its own set of drawbacks. For example, EM is performed on 
dry samples and thus it is not possible to perform degradability measurements with most 
polymeric nanoparticles, such as hydrogels, liposomes etc. DLS, on the other hand, can 
perform measurements in solution but is not very accurate and also is quite limited in terms of 
the dynamic range of particle size and density that can be measured, often requiring large 
amounts of sample volume for each measurement.      
 
2.2 integrin ligands 
2.2.1 Integrins in angiogensis 
Integrins are family of heterodimeric transmembrane proteins that mediate cell surface 
binding to the extracellular matrix (ECM) and intracellular actin cytoskeletal components3. These 
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receptors are formed by pairs of alpha (α) and beta (β) subunits, and have been associated with 
processes ranging from cell structure and adhesion to cell differentiation and survival, which are 
cell behaviors critical to tissue morphogenesis, homeostasis and repair 3-5. It is known that the 
expression of integrins can vary as a function of time and/or environment to support a variety of 
tissue remodeling events. For example, β1 integrin expression was slowly upregulated on the 
brain vessels overtime as vessels gets more mature6. Another example would be αvβ3 
expression in endothelial cells under different environments. Unlike resting endothelial cells 
which express little or no αvβ3, cytokine-activated endothelial cells or cells within malignant 
tumors showed markedly upregulated αvβ37-9. Besides the expression level difference, functions 
of the same integrin can also vary between cell types and/or environmental states. For example, 
α2β1 on platelets is specific for collagen and not laminin10, however, on other cells it can 
recognize both ligands11, 12. 
When we look at endothelial cells specifically, at least seven α and β heterodimers 
(αvβ3, αvβ5, αvβ1, α1β1, α2β1, α3β1 and α5β1) are expressed by endothelial cells and have 
been implicated in vascular morphogenesis and vessel patterning13-15.  Though a complete 
understanding role of all these integrin pairs in the process of angiogenesis is yet to be 
available, the role of β1 and β3 integrins in angiogenesis is important in vascular lumen 
formation16, 17 and tight cell-cell junction formation 16, 18-22. Further, both up-regulation and 
abolishment of β1 and β3integrin activation have shown to be related to pathological 
angiogenesis 3, 20-25. For example, while excessive suprabasal expression of β1 integrin in skin 
has been shown to induce a psoriasis phenotype24, the knockout of β1 integrin resulted in the 
weakening of endothelial cell junctions and induction of blood leakage in a retinal angiogenesis 
assay20. Likewise, the upregulation β3 integrin leads to enhanced endothelial cell permeability26 
while the abolition ofβ3 integrin leads to intrauterine bleeding, defective coronary capillaries, and 
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enhanced tumor angiogenesis (induced by the compensatory VEGF increase after 
β3 knockout)21, 22, 25.   
Certain integrin types have been discovered in cancer progression and seems to be 
related to metastasis and provisional matrix invasion. The increased expression of integrins 
αvβ3 and αvβ5 seems to promote the binding of angiogenic endothelial cells to provisional 
matrix proteins such as vitronectin, fibrinogen, von willebrand factor, osteopontin and fibronectin 
that are deposited in the tumor microenvironment27. On the contrary, other integrinsare 
discovered to positively impact vessel maturation. For example, β1 integrin is shown to promote 
vessel maturation and reduce vessel leakiness in central nervous system6, 20. Likewise, α4β1 
integrin has shown to promote close intercellular interaction between endothelial cells and 
pericytes and thus is required for blood vessel maturation28.Thus, it is extremely important to 
design proper ECM during the angiogenesis process is to present the growing vessels with the 
appropriate integrin binding ligands to generate normal, non-pathological vessels. Materials 
designed for therapeutic angiogenesis, should likewise, provide the appropriate integrin binding 
ligands to support revascularization of diseased tissues. 
 
2.2.2Integrins in biomaterials 
The incorporation of integrin binding peptides derived from natural ECM proteins to 
biomaterials is a popular approach to promote integrin engagement29-34. Integrin-binding RGD 
peptide derived from fibronectin is by far the most widely utilized peptide in the generation of 
materials for cell growth in vitro or promote tissue repair in vivo. Though integrin-binding 
peptides can support cell attachment, migration, and differentiation, they have severely reduced 
binding affinity and specificity compared to the same peptide presented within 3D structure of 
the full-length protein. However, due to the enormous size and complexity of full-length ECM 
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proteins, the expression process is difficult and an alternative approach to present peptide 
motifs in a native 3D structural context is needed. One approach is to express only the integrin 
binding domains from the full-length protein, which is significantly smaller and less complex. For 
example, recombinant fibronectin (Fn) fragments of the 9th type III repeat and 10th type III 
repeat(Fn III9-10) have been expressed to present RGD sequence in the correct 3D structural 
context and improve binding affinity and specificity 35, 36. However, without the rest of the full-
length protein these protein fragments do not contain the natural switches that modulate integrin 
engagement (e.g. native fibronectin can bind several integrin pairs depending on the level of 
extension of the protein37-40) and, thus, lack complete specificity. 
Thus, the fibronectin 9th type III repeat and 10th type III repeat has been engineered 
further to promote α3/α5β1 specific binding and shown to enhance bone formation41, 
mesenchymal stem cell differentiation toward bone35, and modulate epithelial to mesenchymal 
transition42. The extracellular matrix (ECM) has also been successfully engineered to coordinate 
and modulate simultaneous integrin and growth factor signaling to enhance vascularization, 
bone formation, and skin healing 41, 43-48.  
 
2.3Vascular Endothelial Growth Factor (VEGF) 
2.3.1 introduction of VEGF 
The VEGF family, in mammals, consists of five members: VEGF-A, B, C, D and 
Placenta growth factor (PLGF)49-51. VEGF-A was initially discovered as a vascular permeability 
factor (VPF) associated with tumor growth in 198349, 52. In 1989, a few years after, Ferrara and 
Henzel, isolated a protein that induced the proliferation of endothelial cells and called it VEGF. 
Further studies showed that actually VEGF and VPF was the same molecule49, 50. 
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Naturally, splicing of VEGF transcripts results in generation of different protein isoforms 
which regulates affinity for the extracellular matrix (ECM). In particular, the gene encoding 
VEGF-A consists of eight exons that are separated by seven introns, resulting in the generation 
of 206, 189, 183, 165, 148, 145 and 121 amino acids. VEGF-A 165 is the most abundant 
isoform followed by 121 and 189 isoforms. VEGF-A 165 and 121 differs from each other only by 
lack of exon 7 in 121; as a consequence, 165 isoform binds heparan sulfate proteoglycans in 
the extracellular matrix, whereas the 121 does not. Another splice variant of VEGF-A, known as 
VEGF-A 165b, an inhibitory isoform, has been proposed to negatively regulate VEGFR activity. 
In mice, VEGF-A isoforms are one amino acid shorter than their corresponding human 
isoforms49, 50, 52, 53. 
VEGF binds to VEGFRs which are members of the receptor tyrosine kinases (RTKs) 
superfamily and are equipped with an approximately seven immunoglobulin-(Ig)-like domains in 
the extracellular domain. VEGF-A binds to both VEGFR-1(Flt-1) and VEGFR-2(Flk-1/KDR) 
which are primarily expressed in vascular endothelial cells, whilst VEGF-C and D bind to 
VEGFR-3(Flt-4) which is exclusively expressed in lymphatic endothelial cells. VEGFs also 
interact with a family of co-receptors, such as neuropilins (NRP) and HSPG49, 51, 52. 
In Angiogenesis, the first and the most leading cells to start a vessel branch is the “tip 
cell” which is specialized of endothelial cells with their numerous filopodia that respond and 
migrate toward angiogenic stimulus in the microenvironment. Stalk cells, on the other hand, 
proliferate behind the tip cells and form lumen. Tip cells are characterized by the expression of 
VEGF receptor (VEGFR) 2, VEGFR3, platelet-derived growth factor (PDGF)-BB, Delta-like 
ligand-4(Dll4) and others. The communication of tip-to-stalk cell is controlled by NOTCH 
signaling pathway. In response to the VEGF stimuli, tip cells will become specialized by the 
expression of Dll4, which activates Notch in stalk cells, which reduces stalk sensitivity to VEGF 
stimulation, down regulates VEGFR2 signaling and consequently suppresses tip cell phenotype 
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in the neighboring cells. Different VEGF isoform, soluble or matrix-bound forms stimulate more 
lumen formation for the former or more branches formation for the latter54-56. 
 
2.3.2 VEGF regulates vascular development 
Vascular endothelial growth factor (VEGF) is one of the most widely studied and applied 
growth factors that regulate vascular development.  Since a major obstacle in tissue 
regeneration is the lack of stable blood vessel infiltration into engineered tissue implants, VEGF 
has been extensively utilized as a means to induce vascularization57, 58. To prevent diffusion and 
control release, VEGF has been encapsulated59 and electrostatically60 or covalently 
immobilized61-64 to the tissue engineering scaffold. Although the end outcome of enhanced blood 
vessel formation in vivo is achieved63, 64, the characterization of the bioactivity of VEGF-
incorporated matrices in vitro has been limited to cellular migration and proliferation studies 61, 
65, while extensive signaling studies have not been conducted until recently.  
It is now known that growth factors, particularly VEGF, send different signals to 
endothelial cells when presented to their receptors with different degrees of matrix affinity66, 67. 
By changing the growth factor affinity for the matrix, cells will receive different signals and 
behave accordingly. Incorporation of the heparin-binding (i.e. ECM binding) domain in exon 7 
increases matrix affinity68 and leads to induction of migration signaling over proliferative 
signaling67. Developmental biology studies in mouse embryos have shown that the physical 
presentation of VEGF is critical to the development of a normal vasculature. The over-
expression of VEGF with high matrix affinity results in aberrant vessels with reduced vessel 
thickness enhanced vascular branching and increased capillary density69. In contrast, embryos 
expressing VEGF with no matrix affinity displayed poor branching and enlarged vessel 
diameter69. Further, embryos expressing both VEGF with high and no matrix affinity contained a 
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normal vasculature69, indicating that for normal vasculature to result a combination of soluble 
and bound VEGF must be present. 
In the adult, VEGF physical presentation is also critical for angiogenesis; VEGF lacking 
the protease sensitive region but containing the matrix binding domain (resembles high matrix 
affinity VEGF) results in highly branched vessels, while VEGF lacking the matrix binding domain 
(resembles no matrix affinity VEGF) results in vascular hyperplasia and increased 
permeability70. In the adult when VEGF without an ECM binding domain is presented to 
endothelial cells, the resulting blood vessel morphology becomes large and leaky, with 
extensive lumens66. With the ECM binding domain included, VEGF leads to a vessel 
architecture that is smaller in diameter with more branching points. VEGF genetically 
engineered with a deletion of the MMP-cleaveable sequence, but with the ECM binding domain 
intact leads to a dense network of small capillaries66. In a therapeutic setting, neither extreme in 
blood vessel morphology is desirable. Vessels should not be excessively branched (thin 
diameter) or large (thick diameter). For example, to achieve restoration of blood flow in a limb 
ischemic wound models both vessels size and number must increase71. 
 
2.3.3 Delivery of VEGF 
Endothelial cells can be activated by VEGF, which result in increased vessel 
permeability, cell migration and proliferation. However, when utilizing VEGF for therapeutic 
usage, there are three major obstacles. First, VEGF has short life. It has high instability once 
injected as a bolus from the attack of proteases. Second, the dosage matters. Local high 
amount of VEGF may result in deleterious effects including the formation of irregularly shaped 
sac-like vessels associated with massive and highly disruptive edema72 or even formation of 
endothelial cell-derived intramural vascular tumors73. Third, sustained vessel formation needs 
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long-term stimulus. A short VEGF stimulus, if it is not sustained, is associated with the 
regression of the newly formed vessels when discontinued72.  
All these leads to the need for sustained VEGF delivery. From one hand, it reduces the 
VEGF in-activation risk; from the other hand, it prevents negative outcomes from over-dosage 
while gives out long-term stimulation. Many methods are being developed for this purpose, such 
as nanoparticles, hydrogel matrix, etc. All these are good references for our design of delivery 
system in the future. 
PLGA nanoparticles has been utilized for sustained VEGF release and more promising 
result for blood vessel growth has been showed in animal models than soluble VEGF74. The 
89% of VEGF was released gradually from the 200-600 nm PLGA nanoparticles within 4 days. 
Aortic ring angiogenesis assay was utilized to verify the bioactivity of encapsulated VEGF. In a 
mouse femoral artery ischemia model, VEGF-NP-treated limbs showed a significant increase in 
total vessel volume and thickness compared with soluble VEGF and saline conditions while no 
significant difference was found for vessel density or spacing. Interestingly, the unchanged 
anisotropy indicated that VEGF-NP treatment did not change the degree to which vessel were 
oriented in a specific direction. What’s more, when taking VEGF dosing into account, VEGF-
NPs were over an order of magnitude more potent than unencapsulated VEGF in increasing 
blood vessel volume in vivo74. 
Besides nano-scale PLGA particles, PLGA microspheres, the size of which is 5.1±1.3 
um, were also tested in the rat model of cardiac acute-reperfusion-ischemia75.  Unlike low-yield 
nano-scale encapsulation system, the yield of microencapsulation process was over 80% and 
75% of VEGF was being released within 28 days. Treatment with VEGF-MP induced not only 
an increase in capillaries, but also in vessels of greater caliber (arterioles), suggesting that 
prolonged release of VEGF indirectly promotes arteriogenesis by stabilizing the vessels through 
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pericyte and/ or smooth muscles recruitment and proliferation. No hemangioma formation or 
leaking vessels were detected in the VEGF-MP group.  
VEGF-MPs of even bigger size are also utilized in neo-vascularization of stroke cavity76. 
Implantation of VEGF MPs of 50-100 um could stimulate angiogenesis, potentially providing a 
neovascularization of the denove tissue forming inside the lesion cavity and thus increase the 
survival and integration of transplanted cells. However, with the dosage of VEGF-MPs, the 
density of endothelial cells and newly forming blood vessels is much denser than found in 
normal tissue and it is unclear if this will eventually prune some unnecessary branches or if this 
could remain as a hyper-vascularized tissue.  
Later, based on the previous study about rat model of acrdiac acute-reperfusion-
ischemia, PEGylated-PLGA microparticles containing VEGF was fabricated to reduce particle 
phagocytosis in order to increase treatment efficacy77. The bioactivity of VEGF was fully 
preserved. However, the in vivo result in the same model is unclear yet.  
Other materials other than PLGA are also been developed for controlled growth factor 
delivery, such as hyaluronic acid/chitosan nanoparticles78. However, in the dual-growth factor 
delivery system, even though PDGF-BB release was in sustained manner for 1 week, VEGF 
release was uncontrolled. What’s more, in vivo study still needs to be done. 
Hydrogel systems are also being considered as an option for sustained VEGF delivery. 
Particles consisting of VEGF co-lyophilized with trehalose was mixed with injectable, low 
viscosity poly(trimethylene carbonate) for  both in vivo and in vitro experiment79. However, the 
vessels generated were not stable and were reduced in number by 3 weeks, probably due to 
the unsustained and low concentration of VEGF release. Moreover, there was no distinctive 
difference in average blood vessel diameter in the tissue surrounding the VEGF implants and 
that surrounding RSA/trehalose only control.  
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In order to prolong the releasing cycle, nanoparticles together with hydrogel implanting 
system are being tried out. On the platform of PLGA microspheres, both collagen matrix80 and 
fibrin gel 81, 82are being utilized for controlled release of VEGF, as well as commercialized 
Pluronic F127 hydrogel83. The collagen scaffolds, which has constant VEGF releasing rate of 
0.6ng/mg per day, induced a strong angiogenic response in a CAM assay leading to a 2.5 –fold 
increase in the number of newly formed blood vessels compared with that of collagen loaded 
with interspersed VEGF80. For the nanoparticle-fibrin gel complex (NP-Fibrin), instead of loading 
a protein inside the PLGA particles, the authors utilized PLGA nanoparticles as a core that can 
be coated with heparin/pluronic layer, which in turn, interact with VEGF. This system is believed 
to maintain the bioefficacy of loaded protein better than other system by avoiding the o/w/o or 
s/o/w double emulsion method. The system was then loaded inside the fibrin get for sustained 
release81. In a rabbit ischemic hind limb model, VEGF-NP-Fibrin resulted in a significant 
increase in the recovered calf blood pressure, the angiographic score and the density of 
collaterals, as compared with VEGF-Fibrin or Fibrin82. 
PLGA nanospheres are also and using different scaffolds as carrier for VEGF delivery. 
metal stent84, collagen-coated polycarprolactone scaffolds85, mesoporous hydroxyapatite86 , 
porous polyethylene implants87, poly(lactide-co-glycolide) sintered microsphere scaffolds88, 
Elastain/PLGA/PCL89. Besides scaffolds, membrane is also utilized for sustained release of 
VEGF90, heparin cross-linked dematerialized bone matrix91 
Besides delivering VEGF by itself, all kinds of other growth factors are being used to co-
deliver with VEGF for better outcomes. Such as dual delivery of VEGF and PDGF through 
membrane92, VEGF and FGF-2 co-delivery from allografts93. Besides growth factors,  other dual 
delivery system is also being developed, such as VEGF and CoQ(10) 94, sequential delivery of 
VEGF and TAT-HSP27 95, dual delivery of VEGF and MCP-196. 
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2.3.4 Mechanism study of VEGF induced angiogenesis 
The binding of VEGF to VEGFR-2 induces receptor dimerization and 
autophosphorylation of specific intracellular tyrosine residues. In particular, Y1175 and Y1214 
are major phosphorylation sites associated with the activation of the MAPK pathways in 
endothelial cells, activating intracellular signaling cascades critical for proliferation, migration 
and survival97, 98. Matrix-bound VEGF has molecular distinction from soluble VEGF. The 
anchorage of VEGF to a PEG matrix not only elicits prolonged activation of VEGF2, but also 
promotes reciprocal responses on ß1 integrin99.  
Cell signaling data is normally collected by exposing a confluent monolayer of cells to a 
soluble growth factor of interest. The interaction is studied over a course of a few minutes 
because that is the time scale for receptor activation and signal quenching. Recently, the field 
has noticed that matrix-bound growth factors lead to an altered profile of cell reaction. Although 
some groups have studied matrix bound growth factor signaling through plating cells directly on 
surfaces with the immobilized growth factor, this method does not allow cell-signaling studies on 
the order of minutes. In order to circumvent this limitation, others and we have devised 
alternative culturing and exposing platforms. One is based on exposing collagen bound VEGF 
to cells cultured on regular tissue culture plastic. VEGF is entrapped within the collagen gel. The 
loosely bound VEGF is allowed to release and the resulting gel containing matrix bound is 
gently added to the surface of the cells and allowed to incubate for minutes to one hour. From a 
signaling perspective, VEGF-matrix affinity affects the tyrosine phosphorylation profile and 
kinetics of VEGFR-2, along with downstream marker activation. In the soluble case, tyrosine 
residue Y1175 is preferentially phosphorylated, which leads to phospho-AKT activation67. This 
pathway is involved in permeability and survival100, 101. When VEGF is matrix bound, ß1 integrin 
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clusters with VEGFR-2 and phosphorylation of VEGFR2 at Y1214 is extended, as is 
phosphorylation of p3867. These pathways are involved in cell migration100.  
Our laboratory also developed an approach to study covalently immobilized VEGF 
signaling with confluent cells. In our approach, growth factors are bound to a biomimetic SAM 
surface, while a confluent monolayer of cells is grown on a flexible PDMS material. Thus, the 
cells can be exposed to the immobilized growth factor by flipping the cell sheet on top of the 
modified surface. This exposure can be for several minutes and then analyzed. 
 
2.4 Cellular response to nano-patterns 
It has been known for decades that cells respond to topographical cues and signals from 
contact102, 103. In vivo, cells interact with the extracellular matrix in nanometer scale. However, it 
is extremely difficult to study nanometer-scale signals in vivo. Thus, engineering an artificial 
surface that exhibits nano-sized features of biocues is therefore of great interest. 
Distribution of biocues in nano-meter scale has been shown to greatly affect cellular 
outcomes. It has been shown that on 2D surface, integrins on cell surface only cluster and get 
activated when integrin ligands are 58 to 73nm apart104. In 3D culture, distribution of nano-sized 
integrin ligands such as RGD peptides105 were shown to affect cellular and therapeutic 
outcomes as well as nano-sized clusters of vascular endothelial growth factors (VEGF)106. Thus, 
for tissue engineering purposes, it is extremely important to understand and precisely control 
cellular response to nano-scaled distribution of biocues, such as growth factors and integrin 
ligands.  
While the majority of biocues distribution studies focusing on cell-substrate interactions, 
both on micro-scale features107, 108 and nano-scale integrin-ligand features109, 110, studies of 
nano-scaled growth factor distribution are still missing. Unlike integrin activation study which can 
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be easily verified by immunofluorescence staining using a small area (~mm2) nanopatterns, the 
study of nano-scaled growth factor distribution requires large (~cm2) nanopatterns to enable 
protein and mRNA levels of quantification. For example, the use of Western blots, a mainstay 
for cell signaling studies, requires micrograms of protein, which can only be derived from 
thousands of cells growing on a surface of several square centimeters. 
Lots of work have been done to create nano-sized features of biocues on artificial 
surfaces. However, most of the works proposed a small area (~mm2) nanopatterns which 
makes the follow-up cellular studies really difficult due to the small regions and the small 
number of cells on the surface. Thus, to enable cell behavior studies at surfaces and to 
generate statistically relevant data such as cell attachment area and migration speed, nano-
pattern were fabricated by electron-beam lithography (EBL)111, sparse colloidal lithography112-114 
and self-assembly-based approaches104, 115, 116. However, the protein and mRNA expression 
remained un-studied on nano-patterned surfaces. This is mainly due to the difficulty of 
generating ultra-large surfaces, the lack of batch production capability and also the lack of 
consistency between samples.  
VEGF is chosen as a growth factor template because it is known that presentation and 
distribution of growth factors can greatly change the molecular pathway and cellular outcomes. 
Specifically, for VEGF, studies have shown that covalently immobilized VEGF activates 
VEGFR2 pathway differently from soluble VEGF and electrostatically-bond VEGF99. In 
particular, there was an upregulation in the phosphorylation of the p38 kinase, part of the 
signaling cascade associated with endothelial cell migration. This suggests that altering the way 
VEGF in which is presented is sufficient for modulating endothelial cell response. Other study 
also shows that clusters of covalently bound VEGF (cVc) result in enhanced EC sprout 
branching and total network length, compared to soluble VEGF. Thus, it was suggested that 
distribution of VEGF in nano-scale greatly impacts the cellular outcomes, yet no system was 
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available to test out this distribution effects from both mRNA expression and protein expression 
level. 
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Chapter 3  
High-throughput quantification of nanoparticle degradation using computational 
microscopy and its application to drug delivery nanocapsules 
 
 
3.1 Introduction 
Here, we present computational holographic imaging based methods for monitoring 
nanoparticle degradation. These methods enable cost-effective and high-throughput 
quantification of nanoparticle degradation, using a very small volume of sample, e.g., < 15-20 
nL (i.e., at least three orders of magnitude smaller than that is typically required for DLS).27, 28 
We combine the advantages of lensfree holographic microscopy and self-assembled liquid 
nanolenses for rapid imaging and quantification of nanoparticle size over a large field-of-view of 
e.g., >20-30 mm2.29,30,31The nanoparticles under test are deposited on a coverslip followed by 
continuous exposure to polyethylene glycol (PEG) vapor, leading to the formation of nanolenses 
around nanoparticles, which amplify the optical signature of each nanoparticle, enabling its 
detection and size quantification (Figure 3.1). The sample is irradiated from the bottom using a 
programmable array of light-emitting-diodes (LEDs) and the resulting interference patterns (i.e., 
in-line holograms) formed due to the interference between the directly transmitted wave and the 
scattered wave from each nanoparticle-nanolens complex are captured using a complementary 
metal–oxide–semiconductor (CMOS) imager chip, placed at sub mm distance from the sample 
plane. A set of sub-pixel shifted holograms are recorded by turning the illumination LEDs on/off, 
which is then used to digitally synthesize a pixel super-resolved hologram that contains higher 
spatial frequencies of the sample. This pixel super-resolved hologram is reconstructed to yield 
phase and amplitude images of the nanoparticles on the substrate and the phase channel of the 
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sample image is used to quantify the size of the nanoparticles with a sizing accuracy of ±11 
nm30.  
The feasibility of this computational imaging method for monitoring nanoparticle 
degradation is demonstrated using vascular endothelial growth factor (VEGF) core protease-
degradable nanoparticles (Figure 3.2). Growth factors are especially critical for regular cellular 
function and their incorporation within therapeutic materials has been a major focus of recent 
research32. In this work, for proof-of-concept we used VEGF, which has been described as the 
master regulator of angiogenesis33. Protease degradable VEGF nanocapsules were 
synthesized through in situ radical polymerization of acrylate and acrylamide containing 
monomers and protease-sensitive peptide crosslinkers around the VEGF protein core.34,35 The 
final product is a protein-loaded nanoparticle containing 1-2 proteins per nanoparticle that is 
degradable by proteases that recognize the peptide crosslinker used (e.g., plasmin, trypsin). In 
this system one can control the release rate of the protein cargo by using the D enantiomer of 
the protease labile peptide. By changing the amino acids in the peptide crosslinker from L 
enantiomer to D enantiomer, the kinetics of enzymatic cleavage are decreased by 10-fold and 
thus the degradation rate of the nanocapsule is decreased. By mixing L- and D-enantiomer 
peptides in the same nanocapsule we can control the release rate of VEGF over time. However, 
the degradation process for these types of protein-core nanoparticles is hard to 
measure/monitor using existing techniques. First, due to the small batch production amount and 
costly ingredients, DLS is not an ideal testing method since the concentration of the 
nanoparticles is generally close to the lower detection limit of DLS instruments. Second, EM 
readout is feasible for dehydrated samples only and is unable to measure the size of hydrated 
nanoparticles. Third, biochemical assays such as Enzyme Linked Immuno-sorbent Assay 
(ELISA) is not accurate as the protein core gets degraded by proteases once exposed. 
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Therefore, this simultaneous degradation of the protein core and the polymer shell makes 
ELISA assays unreliable 
3.2 Materials and methods 
3.2.1 Materials used 
Concentrated pure VEGF-A was a gift from Genentech. The peptide sequence Lys-Asn-
Arg-Val-Lys of both L- and D- forms were purchased from China Tech Peptide Co. Ltd. 
Polyethylenimine (Linear 2.5KDa) and N-(3- aminopropyl) methacrylamide hydrochloride 
(APPMA) were purchased from Polysciences. Trypsin powder and aprotinin were purchased 
from Sigma-Aldrich. 0.25% Trypsin solution was purchased from Thermo Fisher Scientific. 
Figure 3.1(a) The photograph of the field portable holographic microscope. The device is 
about 25 cm in height and weighs less than 500 g.(b) The schematic of the physical hardware 
of the portable microscope. (c) Pictorial representation of the nanoparticle degradation by 
trypsin. 
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Trypsin amount was tested using Pierce™ Colorimetric Protease Assay Kit.  
 
3.2.2 Field-Portable Holographic On-Chip Microscope 
The schematic of the lensfree holographic on-chip microscope used in this work follows 
previous designs27,31,29,38 and is shown in Figure 3.1a,b. The field portable imaging device was 
constructed using custom-made 3D printed parts30. This super resolution imaging system 
consists of a set of 20 LEDs (controlled by a micro-controller), each of which is coupled to an 
individual optical fiber41, an optical band pass filter with a central wavelength of 532 nm and a 
bandwidth of 10 nm, a mechanical adaptor for sample placement and a CMOS image sensor 
chip with USB readout (Imaging Development Systems UI-1492LE-M, 10 mega-pixels). 
Illumination of the sample was performed from the bottom using one LED at a time, and the 
resulting lensfree transmission holograms of the VEGF nanoparticles are recorded using a 
CMOS camera, which is placed close to the sample, at a distance of less than 1 mm. A custom 
developed LABVIEW program was used to control the entire imaging system. These sub-pixel 
shifted holograms are then used to generate a pixel super-resolved hologram, which is then 
reconstructed to obtain the phase and amplitude images of the nanoparticles37,38,39. 
A reservoir containing PEG-300, attached to the imaging system was utilized to form self 
assembled nanolenses over the nanoparticles. A resistive heater (Omega Engineering, KHLV-
101/10), placed inside the reservoir, is used to heat the PEG-300 solution to the desired 
temperature (e.g., 90-105°C).  A thermistor, interfaced to the main PC through a LabVIEW 
program, is used to monitor and control the temperature of the reservoir. We first acquire a set 
of raw holograms before the PEG condensation, which serves as a baseline to the evaporation 
process. Then, the temperature of the PEG was gradually increased to 95 °C, which results in 
PEG evaporation and condensation around the sample, leading to the formation (i.e., self-
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assembly) of nanolenses around nanoparticles under test. During this deposition process we 
continuously acquire images to monitor and optimize the time-evolution of the nanolenses. 
The image analysis was performed by dividing the field of view into smaller segments. 
The size distributions resulting from these individual segments were later combined to generate 
the final measurement dataset per sample.  This analysis was performed over a subset of 
randomly selected FOVs, each ~5 mm2. The statistical analysis was performed using one-way 
analysis of variance (ANOVA) test and was followed up with the Tukey test42, which compares 
the mean of every time point, for a particular type of nanoparticle, with others and report the P 
value for each comparison. All our analysis was performed with a confidence interval set at 95 
% (P<0.05). These analyses were performed using GraphPad Prism software .43 
 
3.2.3 Vascular Endothelial Growth Factor (VEGF) nanocapsule synthesis 
 
Figure 3.2 Schematic of the vascular endothelial growth factor (VEGF) core protease-degradable 
nanoparticles. 
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The nanocapsules were synthesized using in situ free-radical polymerization as 
previously published34,35. Briefly, to synthesize n(VEGF), VEGF was diluted in a buffer solution 
of 10 mM sodium bicarbonate (pH = 8.55) at a final reaction concentration of 100 μg/ml. 
Acrylamide (AAM) and N-(3-aminopropyl)methacrylamide (APM) and crosslinkers (bisacrylated 
L/D-KNRVK, or methylene bisacrylamide) were subsequently added to the protein solution (at 
the molar ratio of VEGF:AAM:APM:crosslinker = 1:3000:3000:600). Three different crosslinkers 
(L, D or non-degradable) were used to synthesize VEGF nanoparticles with varying degrees of 
degradability (100%L, 100%D or non-degradable). These VEGF nanoparticles were later 
utilized for our degradation measurements reported in our Results section.  
 
3.2.4 VEGF nanoparticle degradation in solution 
VEGF nanocapsules (100 μg/ml) were mixed with equal volume of Tryspin (25 μg/ml, 
100 times dilution from 0.25% Trypsin-EDTA in PBS) and incubated at 37˚C for different time 
points (10, 15, 30 min or 1 day). The samples were subsequently quenched with aprotinin (10 
μg/ml in DI water) and then placed on ice before imaging. Prior to imaging, the samples were 
further diluted by four orders of magnitude.  
 
3.2.5 VEGF nanoparticles degradation on trypsin-coated coverslips 
Trypsin coated coverslips were prepared by first plasma treating them, followed by 20 
min of incubation with 2mg/ml PEI. After aspiration of PEI solution, fresh trypsin (5mg/ml in DI 
water) was added to the surface and incubated on ice for 20 min. The coverslips were dried and 
used shortly after this last step.  
The nanoparticles were first deposited on the coverslip at the desired concentration. This 
was followed by the self-assembly of the nanolenses using PEG vapor, which was monitored 
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using the lensfree holographic on-chip microscope. After the nanolens deposition, the coverslips 
were placed on top of each other to form a sandwich structure and facilitate the interaction 
between the nanoparticle and trypsin, leading to the degradation process.   
3.2.6 Measurement of trypsin amount on a surface 
6mm-diamter PDMS wells were casted and placed on top of each coverslip. The wells 
were then subsequently treated with PEI and trypsin or PEI only as described above. Pierce™ 
Colorimetric Protease Assay Kit was then used to test the amount of trypsin on the coverslips.  
 
3.2.7 DLS Measurements 
DLS measurements were taken with ZetaSizer (Malvern Instruments) at 173° 
backscatter angle. VEGF nanocapsule samples of at least 20 µL volume were measured in the 
precision cell made of quartz SUPRASIL® (Hellma). 
 
3.3 Result and discussions 
To measure the size of the VEGF nanoparticles, we first deposit them onto plasma 
treated hydrophilic coverslips. In order to maintain the hydration of the nanoparticles, they are 
coated with PEG prior to deposition since it has been previously shown that PEG can help 
improve retention of surface water36. The nanoparticles are then exposed to PEG vapor that 
condensate to form droplets around them, acting as nanolenses. These self-assembled 
nanolenses significantly increase the signal to noise ratio of the nanoparticle holograms on the 
CMOS imager, enabling their lensfree detection and size quantification. During each 
experiment, the nanoparticles under test are continuously imaged, during and after the nanolens 
formation, using a custom-developed holographic on-chip microscope as shown in Figure 
3.1a,b. A set of 20 sub-pixel shifted lensfree holograms is recorded using the CMOS imager by 
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digitally changing the illumination LED, and this information is used to digitally synthesize a 
super-resolved hologram, which effectively has sub-micron pixel size, undoing the effect of pixel 
induced spatial undersampling at the hologram plane37,38,39. This super resolved hologram is 
then reconstructed to obtain phase and amplitude images of the nanoparticles on the 
substrate38. The reconstructed phase information is utilized to determine the size of the VEGF 
nanoparticle, by using a linear regression model created with the measured phase information 
of nanoparticles with known size. This entire nanoparticle sizing process is performed using an 
automated segmentation algorithm running in MATLAB30. The algorithm first reconstructs the 
super-resolved images at different heights (z2) from the CMOS image sensor plane and initiates 
the particle counting process. Larger particles that have a higher peak phase value are counted 
first. These counted particles are then digitally removed from each super-resolved image 
(including their twin image artifact) by replacing their amplitude and phase by the background 
average. This process helps with the detection of smaller particles that would have otherwise 
been masked by the optical signatures of larger particles. These steps are repeated until all the 
VEGF nanoparticles are measured.  
Based on our experiments and the above detailed size measurement process, the size 
distributions of VEGF nanoparticles, synthesized using different cross-linkers, L (fast 
degradable), D (slowly degradable) and non-degradable crosslinkers (e.g., bisacrylamide), were 
measured as shown in Figure 3.3. For these experiments, common methods of nanoparticle 
size quantification such as scanning/transmission electron microscopy or atomic force 
microscopy cannot be used for verification, as they are generally used on dry samples, unless 
special sample treatment is used. Therefore, we used DLS technique for independent validation 
of our results – see Supplementary Figure 3.4. Overall, we observed a slightly smaller particle 
size measured using DLS compared to our computational holography measurements. In order 
to verify the accuracy of the DLS instrument, we also measured the particle size of commercially 
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available polystyrene beads that were used for the initial calibration of the holographic imaging 
system and verified using electron microscopy measurements. In these measurements, we also 
consistently observed a lower particle size reading using DLS as shown in Supplementary 
Figure 3.5.  
 
Figure 3.3 The mean particle size of the nanoparticles (L-VEGF, D-VEGF and ND-VEGF) measured by 
our computational holographic on-chip imaging platform following the degradation process at different 
time points. 
 
After these initial experiments, to monitor as a function of time the degradation of VEGF 
nanoparticles with different degradability levels, the particles were incubated with trypsin at 37˚C 
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for 0, 10, 15, 30 min and 1 day. Typsin degradation was quenched with aprotinin. Samples were 
then preserved on ice and immediately used for size analysis. After the first 10 min of 
incubation, the L nanoparticles showed significant decrease in size, indicating a fast 
degradation process, as expected. In comparison to the L nanoparticles, both the D and non-
degradable particles maintained stable size within the first 30 min. However, after 24 hours of 
incubation, D nanoparticles showed a noticeable decrease in size compared to earlier time 
points, indicating the progression of a slow degradation process. On the other hand, non-
degradable nanoparticles maintained their size even after 1 day of incubation (Figure 3.3). 
These observations are consistent with the natural degradation of L and D enantiomer. In 
nature, only L-amino acids are manufactured in cells and corporate into proteins, and D-amino 
acids are found to be strongly resistant to proteolytic degradation40.  
 
Figure 3.4 Comparison between the size distribution of the nanoparticles between Dynamic Light 
Scattering (DLS) (a-c) and our computational imaging system. (d-f). The nanoparticles are as follows: (a), 
(d): L-VEGF; (b), (e): D-VEGF and (c), (f): Nondegradable VEGF. 
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Quite interestingly, during our experiments a significant second peak was observed 
around a particle size of 90-110 nm for some of the particles undergoing the degradation 
process. We hypothesize that this peak is due to trypsin-based aggregation of the particles or 
the monomers. In order to test this hypothesis, we utilized a DLS measurement to study this 
aggregation effect. Briefly, a solution containing VEGF, monomers, and crosslinkers was 
directly incubated with trypsin and monitoring of their mean size was performed by DLS. As 
illustrated in Figure 3.6, a clear aggregation process was also observed using DLS, with a peak 
in size appearing at around 20-40 min. This shows that trypsin aggregates with the cleaved 
monomers and crosslinkers during the incubation process and this leads to the occurrence of 
the second peak in our particle size distribution measurements (Figure 3.3). The average size 
distribution measured at different time points for each of the nanoparticles is also summarized in 
Figure 3.7, where this aggregation related second peak was not included in the average particle 
size.   
 
Figure 3.5  Measurement of particle size distribution of commercialized polystyrene beads using DLS. 
The actual particle size and the measured particle size are mentioned in the figure. 
 
Figure 3.6 DLS measurement of size distribution when trypsin is directly added to nonomer solution. This 
shows that trypsin induces aggregation of the monomers. 
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Next, we created a sandwich assay that enabled us to visualize and quantify enzyme-
triggered degradation of nanoparticles in real time, i.e., continuously. After the nanolens 
deposition on VEGF nanoparticles under test, we placed a trypsin coated coverslip to create a 
sandwich structure, as shown in Figure 3.8. The rationale for this sandwich structure is that 
upon degradation of VEGF nanoparticles, the nanolens around each particle will be destabilized 
leading to a loss in the intensity of its lensfree hologram. Indeed, we observed a significant 
reduction in the intensity of the raw particle holograms for degradable nanoparticles (L 
enantiomer) as shown in Figure 3.9. This reduction in intensity was observed immediately after 
placing the trypsin coated coverslip on the sample and the hologram signal intensity became 
extremely faint within 10 to 15 minutes, quickly approaching to the noise floor of the sensor, 
indicating the degradation of the nanoparticles. Our control experiments with trypsin coated 
coverslips and non-degradable particles as well as polyethyleneimine (PEI) coated coverslips 
with degradable nanoparticles, did not show a significant change in their particle hologram 
intensity, as shown in Figure 3.10. It should be emphasized that this nanoparticle degradation 
was observed only when a high concentration of trypsin was used, e.g., ~ 40-50 ng per mm2. 
The need for this high concentration may be due to the limited contact surface between the 
nanoparticles under test and the trypsin coated surface area.  
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Figure 3.7 Average size of the nanoparticles following the degradation process, measured by our 
computational holographic on-chip imaging platform. The analysis was performed by averaging the sizes 
of over 350 nanoparticles, for all the samples, except the 1-day L-VEGF sample, which had lower 
recovery, with ~80 particles. Error bars denote the standard deviation. The P values are denoted as  **: 
P<0.0015; **** : P<0.0001. 
 
Figure 3.8 Schematic of the sandwich structure, depicting the interaction between each nanoparticle-
nanolens complex and the trypsin on the surface of a substrate. 
Our first method of sampling a subset of nanoparticles undergoing degradation, and 
computationally sizing them subsequently is more general compared to the second approach 
that we presented, and can be used for all types of nanoparticles with any degradation 
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mechanism. This method mainly focuses on the characterization of nanoparticles post-
degradation. It gives a clear view of the final outcome of degradation process, however, no real-
time visualization is possible. Unlike the first method, our second method starts monitoring the 
nanoparticles before any degradation happens and facilitates real-time visualization of the entire 
process. Also, this unique sandwich assay requires an even smaller amount of sample volume 
compared to the first method. However, this 2D sandwich based method can only be applicable 
to a select group of nanoparticles, which can degrade using e.g., light, magnetic field etc. or 
antagonists that can be introduced by a coverslip/substrate. 
 
Figure 3.9 Monitoring the changes in the intensity of the lensfree holograms of the L (fast-degradable) 
VEGF nanoparticle/nanolens complexes following their contact with the trypsin-coated surface in the 
sandwich structure. The arrows indicate the selected nanoparticles used for the subsequent analysis 
reported in Figure 3.10. 
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Figure 3.10 Temporal changes in the intensity of the lensfree holograms, each corresponding to individual 
nanoparticles, after their interaction with the trypsin coated surface. The color represents the particles 
selected in Figure 3.9. 
3.4 Conclusions 
By using our computation holographic microscopy based method, these obstacles are 
overcome. We used two different testing methods to monitor and quantify the degradation of 
VEGF nanoparticles. The first method involves sizing the nanoparticles by discretely sampling 
the synthesis solution at different time points after addition of proteases. A second method using 
a sandwich assay was developed to monitor the live degradation process in a continuous 
manner by placing a trypsin coated coverslip on the nanoparticle/nanolens complex, also 
imaged by our computational holographic microscope. These computational imaging 
experiments were performed on both degradable and non-degradable nanoparticles, showing a 
drastic change to the polymer matrix bound together by degradable crosslinkers compared to 
the nondegradable ones. Overall, this computational holographic imaging based nanoparticle 
monitoring platform provides a much needed, cost effective and high-throughput method to 
quantify the degradation process of any type of nanoparticle using very small amounts of 
sample volume.  
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Chapter 4  
Integrin stimulation from bioengineered scaffolds dictates vascular patterning 
and reduces VEGF induced vascular permeability after stroke 
 
 
4.1 Introduction 
The design of therapeutic angiogenic materials to treat cardiovascular diseases, such as 
deficient blood supply to the heart, limbs, and brain, has primarily been driven by the delivery of 
angiogenic factors within a scaffold. Optimization of these materials has been focused 
dominantly on controlling angiogenic factor release or presentation and modulating bulk 
physical properties. Although adhesive ligands that promote integrin binding are generally 
incorporated within therapeutic angiogenic materials, the subsequent cell-material interaction 
has not been explored as an angiogenic signal. 
This present work shows for the first time that specific integrin activation from a 
biomaterial can be harnessed to direct vascular patterning in vitro and in vivo leading to 
enhanced reperfusion of the brain after stroke. 
Integrin binding is a fundamental design parameter for engineering matrices for tissue 
repair and regeneration. The incorporation of integrin binding molecules within engineered 
matrices ranges from peptides such as RGD117, to protein fragments118, and natural proteins119, 
with the primary purpose to promote cell spreading and migration within these matrices. 
However, integrin binding ligands are often overlooked as bioactive cues in capable of dictating 
morphogenesis and guiding tissue repair. Our work shows for the first time that integrin 
stimulation from engineered matrices is a morphogenic signal that can be harnessed to 
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generate either a normal vasculature or a diseased vasculature depending on the integrin being 
engaged. 
Immediately following vascular injury, wounds are not filled with collagen but rather 
provisional matrices comprised of fibrin and fibronectin. Fibronectin is the major ECM 
constituent in the early, pre-vascularized wound. In our study, recombinant fibronectin fragments of 
the 9th type III repeat (Fn III9) and 10th type III repeat (Fn III10) were designed to preferentially bind 
α3/α5β1 or αvβ3 integrin respectively. To achieve α3/α5β1 specificity, the thermodynamic stability of Fn 
III9 was increased through a leucine to proline point mutation at position 1408. This mutation has been 
previously shown to stabilize the integrin-binding domain of fibronectin, i.e. Fn III9-10, and enhance its 
binding selectivity to synergy-dependent b1 integrins, including both a5b1 and a3b135, 40, 120.To achieve 
αvβ3 integrin specificity, four (4) glycine residues were then inserted into the linker region between Fn III9 
and Fn III10.  The 4xGly insertion both physically separates the synergy (PHSRN) and RGD sites located 
on Fn III9 and Fn III10, respectively, and introduces torsional flexibility between the two domains, 
resulting in a complete disruption of α3/α5β1 integrin binding and promoting a αvβ3 integrin preference. 
Though both recombinant fragments can theoretically bind αvβ3 integrin via the RGD sequence, we and 
others consistently observe a preference of the stabilized mutant to bind synergy-dependent integrins, 
like α5β1 integrin in cell material interactions42, 121. In this manuscript, we called the Leu-Pro mutated, or 
stabilized, fragment 9*10 and the 4xGly insertion mutated fragment 9(4G)10. For ease of immobilization 
onto surfaces and incorporation into natural and synthetic hydrogel biomaterials both fragments were 
produced with an N-terminal cysteine residue to allow Michael type addition modifications and a factor 
XIIIa substrate sequence, consisting of residues 1–8 of the protein alpha2 plasmin inhibitor (α2PI1-8, 
NQEQVSPL) 122 to allow enzymatic conjugation. 
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4.2 Materials and methods 
4.2.1 Recombinant fibronectin fragments 
Recombinant fibronectin fragments of the 9th type III repeat (Fn III9) and 10th type III 
repeat (Fn III10) were designed to preferentially bind α3/α5β1 or αvβ3 integrin respectively. To 
achieve α3/α5β1 specificity, the thermodynamic stability of Fn III9 was increased through a 
leucine to proline point mutation at position 1408. This mutation has been previously shown to 
stabilize the integrin-binding domain of fibronectin, i.e. Fn III9-10, and enhance its binding 
selectivity to synergy-dependent b1 integrins, including both a5b1 and a3b135, 40, 120.To achieve 
αvβ3 integrin specificity, four (4) glycine residues were then inserted into the linker region 
between Fn III9 and Fn III10.  The 4xGly insertion both physically separates the synergy 
(PHSRN) and RGD sites located on Fn III9 and Fn III10, respectively, and introduces torsional 
flexibility between the two domains, resulting in a complete disruption of α3/α5β1 integrin 
binding and promoting a αvβ3 integrin preference. Though both recombinant fragments can 
theoretically bind αvβ3 integrin via the RGD sequence, we and others consistently observe a 
preference of the stabilized mutant to bind synergy-dependent integrins, like α5β1 integrin in cell 
material interactions42, 121. In this manuscript, we called the Leu-Pro mutated, or stabilized, 
fragment 9*10 and the 4xGly insertion mutated fragment 9(4G)10. For ease of immobilization 
onto surfaces and incorporation into natural and synthetic hydrogel biomaterials both fragments 
were produced with an N-terminal cysteine residue to allow Michael type addition modifications 
and a factor XIIIa substrate sequence, consisting of residues 1–8 of the protein alpha2 plasmin 
inhibitor (α2PI1-8, NQEQVSPL) 122 to allow enzymatic conjugation. 
The expression system for these recombinant Fn fragments has been optimized from 
prior publications (Markowski et al.) to create a high throughput production process121. The 
expression vectors were transformed into MDS™42 LowMut ΔrecA (6262) chemically 
competent cells and individual clones were picked for successive expansion and increased 
 40 
protein yields. Transformed cells were grown in 2xYT media with Kanamycin (50 µg/mL) and 
protein production was induced by addition of 1.5mM IPTG. Incubation at 37°C with shaking for 
approximately 16 hours allows maximal protein production. Cultures were then centrifuged and 
lysed via sonication and freeze-thaw cycling. Recombinant Fn9-10-tdtomato-10 His were 
purified on a HisTrap nickel column (AKTSA Start, GE Healthcare) via affinity chromatography. 
Tdtomato and 10-His tag were removed by utilizing the thrombin cleavage site and bovine 
thrombin (Sigma-Aldrich) to separate the fragment and the tdtomato fusion protein. A 
Benzamidine column bound the free bovine thrombin and the His tag allows collection of C-
terminal tdtomato in the HisTrap again and the Fn fragments (Fn9*10 or Fn9(4G)10) were 
released. The purity of Fn9-10 protein fragments was then analyzed by SDS-PAGE as 
mentioned in previous works35, 42.  
 
 
4.2.2 Immobilization of Fn9*10 or Fn9(4G)10 on homogenous gold surface 
Standard laboratory microscope glass slides were sequentially washed with acetone, 
isopropyl alcohol and methanol before gold deposition in e-beam evaporator. Deposition 
parameter: 5nm titanium at 0.3 Å/s deposition rate, followed by 30 nm gold at 0.5 Å/s deposition 
rate. Gold slides were then functionalized with 1% HS-C11-EG6-NH2(11-
Mercaptoundecyl)hexa(ethylene glycol) amine, ProChimia Surfaces) and 99% HS-C11-EG4-OH 
(11-Mercaptoundecyl)tetra(ethylene glycol), Sigma-Aldrich). A total of 100mg of EMCH (N-[e-
Maleimidocaproic acid]hydrazide, Fisher Scientific, PI-22106) was first dissolved in anhydrous 
DMSO(Dimethyl sulfoxide) to make 50Mm stock. 5 mg/ml Heparin (Alfa Aesar, A16198) solution 
in 100mM 2-(N-morpholino)ethanesulfonic acid (MES) pH6 buffer was then mixed with EMCH, 
NHS (N-Hydroxysuccinimide ,Sigma-Aldrich)  and EDC (1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride, Fisher Scientific) sequentially. Mole ratio of COOH in heparin/ 
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EMCH/ NHS/EDC=1:1:1:10. The reaction continued for 6 hours with gentle shaking followed by 
dialysis. The dialyzed samples were then lyophilized and sent for NMR for modification 
verification. The modified heparin was then conjugated to SAMs (99% EG-OH, 1% EG-NH2) 
formed on gold slides via EDC/NHS method as previously stated. Either Fn9*10 or Fn9(4G)10 
(1000ng/slide, 53.3ng/ cm2) was incubated with the modified heparin-coated surfaces overnight 
at 4 °C, followed by three PBS washes. 
 
4.2.3 Enzyme-linked immunosorbent assay (ELISA) on Fn9*10 or Fn9(4G)10 immobilized gold 
surface 
Modified gold surfaces was Argon-dried and then assembled together with PDMS sheet 
that has two 8mm circular wells followed by 60ul/well 0.1%BSA-PBS as blocking buffer for 1 
hour at room temperature. After aspiration, 60ul/well of Anti-Fibronectin primary antibody 
(1:2000 dilution in blocking buffer, ab299, Abcam) was added for 2 hours at room temperature. 
After 3 washes using 0.05% Tween-20+PBS (washing buffer), 60ul/well of streptavidin-HRP 
(1:5000 dilution in blocking buffer, #DY998, R&D Systems) was added for 1hour at room 
temperature. After 3 washes, 60ul/well of TMB substrate (#7004L, Cell signaling) was added, 
incubated for 8 min in dark and then transferred to 96-well plates containing 1M H2SO4. The 
absorbance was measured at 450nm and normalized against absorbance at 550nm. 
 
4.2.4 Cell proliferation assay 
Slides immobilized with Fn9*10 or Fn9(4G)10 were washed twice with sterile PBS and 
then blew dry in cell culture hood for well assembly with 8-wells ibidi sticky-bottom device (ibidi, 
#80828). A total of 5000 HUVECs in EGM-2 stripped off fibronectin were seeded in each well 
with or without 2ng/ml of VEGF and the cell number was assayed after 48 hours using Cyquant 
assay. A minimum of n=8 per condition was used in this experiment. 
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4.2.5 Cell migration assay 
Slides were then washed twice with sterile PBS and then blew dry in cell culture hood for 
well assembly with PDMS sheets containing two 8mm holes. 5000 HUVECs pre-stained with 
SP-DilC18(3) lipophilic red fluorescence dye (Life Technologies) were seeded in each PDMS 
well on surface in EGM-2 w/o Fibronectin/VEGF medium and allowed for cell attachment for 3 
hours in cell incubator. The slides were then transferred into incubation system of Zeiss LSM 
780 confocal for 10x phase time-lapse tracking. Images were taken at 4 different locations over 
time span of 7 hours with 15 min interval. A MATLAB program was then developed to track the 
strongest lipid signal. Basically, after circling out manually the target cells, the program tracks 
the brightest lipid stain in the area to create the cell migration path and calculated cell migration 
distance. A minimum of n=64 in each condition was used to quantify. 
 
4.2.62D Immunofluorescence Staining on Fragments Coated Cell Culture Plates 
Glass-bottom 24-well plates were first incubated with 500μl of 2 μM Fn9*10 or 
Fn9(4G)10 per well overnight. Wells were incubated with 5% BSA-PBS for 1 hour at room 
temperature before the seeding of HUVECs which were pre-starved in EBM-2 media for 6 
hours. A total of 50000 HUVECs in EGM-2 stripped off fibronectin were seeded in each well 
without VEGF and fixed after 18 hrs. Cell samples were first fixed in 1% PFA for 20 min, 
washed twice with PBS for 5 min. Samples were incubated at room temperature for 30min in 
blocking buffer: PBS+ 5% Normal Goat Serum. Primary antibodies were prepared as follows in 
blocking buffer: Mouse anti-αvβ3 (clone LM609, Millipore; MAB1976) – 1:100, Mouse anti-
α5β1(clone HA5, Millipore; MAB1999) – 1:100. Samples were incubated with primary antibodies 
overnight at 4°C, followed by Secondary antibodies (1:500) and 2µg/ml DAPI for 1 hour in the 
dark at room temperature. Imaging was performed using a Nikon C2 confocal. 
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4.2.72D Immunofluorescence Staining on Fragments immobilized Gold Surfaces 
Slides immobilized with Fn9*10 or Fn9(4G)10 were washed twice with sterile PBS and 
then blew dry in cell culture hood for well assembly with 12-well customized white Teflon wells. 
A total of 5000 HUVECs in EGM-2 stripped off fibronectin were seeded in each well with or 
without 2ng/ml of VEGF and fixed after 24 hrs. Cell samples were first fixed in 4% PFA for 15 
min, washed twice with PBS for 5 min each before incubating with PBS+0.1% Triton for 3 min. 
After washing the samples again with PBS, samples were incubated at room temperature for 
30min in blocking buffer: PBS+ 2% Normal Goat Serum. Primary antibodies were prepared as 
follows in blocking buffer: Rabbit anti-mouse and human VEGFR-2 (Cell Signaling Technology; 
#2479L) – 1:200, Mouse anti-human PECAM-1 (R&D; #BBA7) – 1:200, Monoclonal mouse anti-
Vinculin antibody (Sigma-Aldrich, #V9131) – 1:400, Mouse anti-αvβ3 antibody (EMD Millipore, 
MAB1976) – 1:200. Samples were incubated with primary antibodies overnight at 4°C, followed 
by Secondary antibodies (1:500) and 2µg/ml DAPI for 1 hour in the dark at room temperature. 
Imaging was performed using a Zeiss confocal and images were analyzed using Image J. 
 
4.2.8Sprouting Assay with blank, full length Fibronectin, Fn9*10 or Fn9(4G)10 fibrin gels 
Fibrin bead assay HUVEC were mixed with dextran-coated Cytodex 3 microcarriers 
(Amersham Pharmacia Biotech) at a concentration of 400 HUVEC per bead in 1 ml of EGM-2 
medium (Clonetics). Beads with cells were shaken gently every 20 min for 4h at 37°C and 5% 
CO2. After incubating, beads with cells were transferred to a 25-cm2 tissue culture ﬂask (BD 
Biosciences) and left for 12–16 h in 5 ml of EGM-2 at 37°C and 5% CO2. The following day, 
beads with cells were collected and washed three times with 1 ml of EGM-2 w/o Fibronectin and 
resuspended at a concentration of 500 beads/ml in 2 mg/ml ﬁbrinogen (Fib1 or Fib3), 1 U /ml 
factor XIII and 0.04 U/ml aprotinin at a pH of 7.4 with or without 2 µM Fn9*10, 2 µM Fn9(4G)10, 
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0.54 µM full length Fibronectin (Millipore, FC010). A total of 250 ul of this fibrinogen/bead 
solution was added to 0.16 units of thrombin in one well of glass-bottom 24-well plates. 
Fibrinogen/bead solution was allowed to clot for 5 min at room temperature and then at 37°C 
and 5% CO2 for 20 min. EGM-2 w/o Fibronectin was added to each well and equilibrated with 
the ﬁbrin clot for 30 min at 37°C and 5% CO2. Medium was removed from the well and replaced 
with 1 ml of fresh EGM-2 w/o Fibronectin. A total of 20,000 HDFs were plated on top of the clot 
and the medium was changed every other day. Bead assays were monitored for 7 days. At least 
three independent gels were evaluated per condition per sprouting experiment. Quantifications 
of at least 5 beads from each gel were analyzed (only sprouts with a length of one bead 
diameter were included). Since beads were seeded sparsely (25-40 beads within 250ul of total 
gel volume) and each bead was surrounded by its own microenvironment, we consider each 
bead as an independent sprouting sample. Additionally, sprouting data were analyzed across 
experiments performed in different days taking each day as one biological replicate. The trends 
from both types of analyses are the same.  
 
4.2.9 Quantification of Vessels and Tip Cells in Sprouting Assay 
High-resolution images of beads were captured on a Nikon Confocal C2 with a 10X 
objective. The advantage of taking images at this magnification is the depth of field which 
includes all sprouts in focus. Images are then analyzed in NIH ImageJ. The number of sprouts 
per bead, the number of branches per bead, length of total network per bead and branch cluster 
per bead were counted. Only sprouts with a length of one bead diameter were included. A 
minimum of n=15 was used for each condition from 3 independent wells.  
Tip cells images were captured on a Nikon Confocal C2 with a 60X objective. Images 
are then analyzed in NIH ImageJ. The number of filopidia per tip were counted. A minimum of 
n=19 was used for each condition from 3 independent wells.  
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4.2.10Sprouting Assay with RGD Presence 
Sprouting assay was performed as previously described in Fib3 fibrin gels with 200, 500 
or 1000 µM of α2PI1-8-RGD (H-NQEQVSPLRGDSPG-NH2, GenScript). 
 
4.2.11Anastomosis Sprouting Assay with Fn9*10 and Fn9(4G)10 
EGFP-HUVEC were mixed with dextran-coated Cytodex 3 microcarriers at a 
concentration of 400 HUVEC per bead in 1 ml of EGM-2 medium. Beads with cells were shaken 
gently every 20 min for 4h at 37°C and 5% CO2. Beads with cells were then transferred to a 25-
cm2 tissue culture ﬂask and left for 12–16 h in 5 ml of EGM-2 at 37°C and 5% CO2. The 
following day, beads with cells were washed three times with 1 ml of EGM-2 w/o Fibronectin 
and resuspended at a concentration of 500 beads/ml in 2 mg/ml Fib3 ﬁbrinogen, 1 U /ml factor 
XIII and 0.04 U/ml aprotinin, 80,000 cells/ml HDF at a pH of 7.4 with 2 µM of Fn9*10 or 
Fn9(4G)10. 250 ul of this fibrinogen/bead solution was added to 0.16 units of thrombin in one 
well of glass-bottom 24-well plates. Fibrinogen/ HUVEC bead/ HDF cells solution was allowed to 
clot for 5 min at room temperature and then at 37°C and 5% CO2 for 20 min. EGM-2 w/o 
Fibronectin was added to each well and equilibrated with the ﬁbrin clot for 30 min at 37°C and 
5% CO2. Medium was removed from the well and replaced with 1 ml of fresh EGM-2 w/o 
Fibronectin and later was changed every other day. Bead assays were monitored for 11 days. 
Three independent wells were evaluated per condition. Tip-tip contact distribution from each 
condition were analyzed within the 170μm of working distance of 60x objective. 
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4.2.12Flow Cytometry 
HUVEC cells were harvested from 25 cm2 cell culture flask using 1ml of 2mg/ml 
Collagenase (Thermo Fisher Scientific, ICN1951091) for incubation of 30min at 37°C. The 
reaction was later quenched with 1mM EDTA in PBS for 5min before centrifugation at 200g for 
5min. 60,000 cells per well were then added to 96-well round-bottom plate (Corning, 3365) 
which already contained 100 µl of serial dilution of P3G8 (Developmental Studies Hybridoma 
Bank) starting at concentration of 1µg/ml. The plate was then incubated in cell incubator for 
30min before centrifuged at 1200rpm for 2min. 200 µl of FACS buffer (2% FBS in PBS) per well 
was then added to resuspend the cells pellet.  This washing step was repeated twice before 
Goat-anti-Mouse AF488 was diluted in 1:4000 and added into the wells. The secondary 
antibody incubation was done in dark outside of incubator for 20min. Cells were then 
centrifuged and washed 3 times like described above. The final cell pellets were resuspended in 
FACS buffer.Analysis was performed using a MACS Quant VYB and the data was analyzed 
using FLOWJO. Triplicates were done for each condition with at least 9700 events/sample. The 
data was gated such that the negative control had 0.5% positive events. 
 
4.2.13Integrin Blocking Sprouting Assay 
Sprouting assays were performed as previously described.  
For Fn9*10 gels, HUVEC beads were suspended at a concentration of 500 beads/ml in 
2 mg/ml ﬁbrinogen (Fib1 or Fib3), 1 U /ml factor XIII, 0.04 U/ml aprotinin and 2 µM (high 
dosage) or 0.267 µM (low dosage) Fn9*10 at a pH of 7.4 with or without 5µg/ml of β1 integrin 
blocking antibody (AIIB2, Developmental Studies Hybridoma Bank) or α5 integrin blocking 
antibody (BIIG2, Developmental Studies Hybridoma Bank). The blocking antibody (5µg/ml) in 
fresh fibronectin-free EGM-2 medium was replenished every day. 
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For Fn9(4G)10 gels, HUVEC beads were suspended at a concentration of 500 beads/ml 
in 2 mg/ml ﬁbrinogen (Fib1 or Fib3), 1 U /ml factor XIII, 0.04 U/ml aprotinin and 2 µM (high 
dosage) or 0.239 µM (low dosage) Fn9(4G)10 at a pH of 7.4 with or without 5µg/ml of β3 
integrin blocking antibody (9H5, Developmental Studies Hybridoma Bank) or αv integrin 
blocking antibody (P3G8, Developmental Studies Hybridoma Bank). The blocking antibody 
(5µg/ml) in fresh fibronectin-free EGM-2 medium was replenished every day. 
 
4.2.14VE-cadherin Staining on 3D Integrin-Blocking Assay 
 Gel samples were first fixed in 1% PFA for 15 min, blocked for 2 hours at room 
temperature in a blocking buffer of PBS+ 0.05% Tween-20 + 5% Normal Goat Serum. Samples 
were then incubated in a primary antibody directed againt VE Cadherin (Rabbit, Abcam; 
ab33168, 1:200) overnight at 4°C, followed by a secondary antibody (1:500) and 2µg/ml DAPI 
for 1 hour. Imaging was performed using a Nikon C2 confocal and images were analyzed using 
Image J. 
 
4.2.15VE-cadherin Staining on 2D Fragments-Coated Surfaces 
A total of 500ul of 2 µM Fn9*10 or Fn9(4G)10 in PBS buffer was added into sterile 24 
well glass-bottom plates (MatTek Corporation) for 1 hour in cell incubator, followed by 0.1% 
heat-deactivated sterile BSA-PBS buffer for 1 hour. HUVECs cells pre-starved for 6 hours in 
EBM-2 were collected, resupspended in EGM-2 medium w/o Fibronectin either with or without 
VEGF and seeded into fragments and BSA treated wells. Cell density of 50,000 cells per well in 
24-well glass-bottom plates was used. After 12 hours, cells were fixed in 1% PFA for 15 min and 
stained for VE-cadherin. Cell samples were first fixed in 1% PFA for 15 min, washed three times 
with 1XPBS for 5 min before blocked for 2 hrs at room temperature in blocking buffer: 1XPBS+ 
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0.1%BSA + 0.1% Tween-20 + 0.3M Glycine+ 10% Normal Goat Serum. Samples were 
incubated in a primary antibody Rabbit anti- VE Cadherin (Abcam; ab3316, 1:500) overnight at 
4°C, followed by a secondary antibodies Donkey anti-Rabbit (1:500) and 2µg/ml DAPI for 1 
hour. Imaging was performed using a Nikon C2 confocal and images were analyzed using 
Image J. At least three independent wells were evaluated per condition. Grey value distributions 
were analyzed using Image J. 
 
4.2.16Hyaluronic Acid-Acrylate Synthesis 
Sodium hyaluronan was modified to contain acrylate functionalities as previously 
described123. Briefly, hyaluronic acid (2.0 g, 5.28 mmol, 60 kDa) was reacted with 18.0 g 
(105.5 mmol) of adipic acid dihydrazide (ADH) at pH 4.75 in the presence of 4.0 g (20 mmol) of 
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride overnight and purified through 
dialysis (8000 MWCO) against a 100–0 mM salt gradient water for 2 days. The purified 
intermediate (HA-ADH) was lyophilized and stored at −20 °C until used. Approximately 60% of 
the carboxyl groups were modified with ADH, which was determined using 1H-NMR (D2O) by 
taking the ratio of peaks at δ = 1.6 and 2.3 corresponding to the eight hydrogens of the 
methylene groups on the ADH to the singlet peak of the acetyl methyl protons in HA (δ = 1.88). 
HA-ADH (1.9 g) was reacted with N-acryloxysuccinimide (NHS-Ac) (1.33 g, 4.4 mmol) in 
HEPES buffer (10 mM HEPES, 150 mM NaCl, 10 mM EDTA, pH 7.2) overnight and purified 
through dialysis against a 100–0 mM salt gradient for 1 day, then against DI water for 3–4 days 
before lyophilization. The degree of acrylation was determined to be ∼10% using 1H-NMR (D2O) 
by taking the ratio of the multiplet peak at δ = 6.2 corresponding to the cis- and trans-acrylate 
hydrogens to the singlet peak of the acetyl methyl protons in HA (δ = 1.88) (Data not shown 
here). 
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4.2.17Vascular Endothelial Growth Factor Nanocapsules Synthesis 
The nanocapsules were synthesized using in situ free-radical polymerization as 
previously published by our group. Briefly, to synthesize n(VEGF), VEGF was diluted in a buffer 
solution of 10 × 10
-3
M sodium bicarbonate (pH = 8.55) at a final reaction concentration of 100 
μg ml
-1
. Acrylamide (AAM) and N-(3-aminopropyl)methacrylamide (APM) and crosslinkers 
(bisacrylated L/D-KNRVK, or methylene bisacrylamide) were subsequently added to the protein 
solution (at the molar ratio of VEGF:AAM:APM:crosslinker = 1:3000:3000:600). Different ratio of 
L/D crosslinkers were used to generated 100%, 75%, 50% and 25% n(VEGF). Later, these 
n(VEGF)s were mixed at equal amount for controlled release of VEGF. 
 
4.2.18HA Hydrogel Storage Modulus Optimization 
HA hydrogel was formed in 0.3M pH 8.2 HEPES buffer, following steps as below.  
Tube 1: HA-ADH-Ac in HEPES buffer (ADH modification is 65.62% and Ac modification 
is 13.33%) was incubated with fibronectin fragments of for 20 min. Tube 2: Poly(ethylene glycol) 
dithiol (MW 1000, Sigma-Aldrich, #717142) and Alexa Fluor 555 C2 Maleimide (Thermo Fisher 
Scientific, #A-20346) solutions in HEPES buffer were mixed together at equal moles for 20 min 
to generate fresh SH-PEG-AF555. Tube 1 was then mixed with Tube 2 mixture for 20 min 
before nanocapsules of VEGF was added. Di-cysteine modified Matrix Metallo-protease (MMP) 
(Ac-GCRDGPQGIWGQDRCG-NH2) (GenScript) sensitive crosslinker was added in the end to 
initiate gelation. Gelation was allowed for 30 min at 37°C. To determine the storage modulus 
range, gels with different thiol to acrylate (R ratio) were tested.Pre-swelled HA hydrogels (8mm 
in diameter and 1mm thickness) were placed between 8mm (diameter) rheological discs at 
normal force of 0.01N using a plate-to-plate rheometer (Anton paar physica mcr 301 
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Rheometer). The storage modulus was measured under constant 1% amplitude, from 10 to 0.1 
rad/s angular frequency. Three independent gels were casted and evaluated per R ratio 
condition. 
 
4.2.19HA Gel Formula for SubQ Mice Model 
HA hydrogel was synthesized as described above. Briefly, HA-ADH-Ac is dissolved into 
0.08mg/ml solution in 0.3 M HEPES buffer (pH8.2). The solution is then incubated with Fn9*10 
or Fn9(4G)10 for 20 min. SH-PEG-AF555, nanoVEGF, and MMP crosslinker are added 
sequentially. R ratio of 0.60 was used for animal experiment.  
Table 4.1 HA Gel Formula for SubQ Mice Model 
HA-ADH-Ac 3.5 wt% 
MMP crosslinker 3.335mM 
SH-PEG-AF555 10μM 
Fn9*10 or Fn9(4G)10 10μM 
VEGF nanocapsules 200ng/50μl Gel 
 
4.2.20SubQ Mice Model 
G*Power was first used to compute the required sample size. Using two-tailed t-test on 
previous SubQ data and high variance assumption for the tortuosity measurement, we found the 
required sample size to be within the range of 3 to 6. We choose to start with 6 animals per 
group.  
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All in vivo studies were conducted in compliance with the NIH Guide for Care and Use of 
Laboratory Animals and UCLA ARC standards. Seven to nine week old male Balb/c mice were 
used to study cellular infiltration and blood vessel formation in HA gels with different fibronectin 
fragments since this strain has been used for wound healing and angiogenesis assay124. Mice 
were anesthetized with 2–3% isoflurane in an induction chamber and kept under anesthesia 
during the whole surgery. The back of the mouse was shaved, washed with betadine and 70% 
ethanol. Two lateral incisions appropriate to the size of the implant were made in the skin (one 
on each side of the midline of the animal) using scissors. Two subcutaneous pockets were 
subsequently created by blunt dissection using rounded-end scissors. The hydrogels were 
inserted into each respective subcutaneous pocket and closed with a single wound clip. All 
animals were administered with an anti-inflammatory agent (Carprofen, Rimadyl, 5mg/kg) for 
the first 48 hours after surgery. At day 7, the clips were taken off. After 2 weeks, each mouse 
was injected with 100ul of 1mg/ml of isolectin GS-IB4-AF488 conjugate (ThermoFisher 
Scientific, #I21411) through the left external jugular vein before and sacrificed by isoflurane 
overdose. The implant hydrogels (total of 6 blank gels, 6 Fn9*10 gels, 6 Fn9(4G)10 gels) were 
then collected and fixed in 1% PFA for 16 hours at 4°C. Due to the variance in sample collection 
process, the membrane layers attached to the implants were intact only for 4 gel implant per 
condition. Thus, for confocal imaging, only those with intact membranes were analyzed. For 
sheet confocal analysis, it doesn’t require the intact cell membrane the focus was on vessel 
infiltration, thus we used 6 individual implant gels per condition for quantification purposes. 
4.2.21 SubQ Mice Model Quantification 
Samples were first imaged using a Nikon C2 confocal to visualize the superficial 
vascular network on the surface of the sample. For space filling analysis, confocal images were 
converted to binary images and analyzed using the Matlab software package. Images were 
divided into equally sized regions using window sizes of 256 pixels in length for 4x4 heat map 
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images. The fraction of non-white pixels in each region was calculated and utilized to generate 
an associated heat map indicating the degree of vascular signaling present in that region. Color 
map scale bars were set in grayscale. 
 
Light sheet microscopy was then used to image the vascular infiltration in the implanted 
gel. Briefly, fixed hydrogel samples were inserted into a transparent 6mm tube. The tubes were 
then filled with 0.3% agarose solution in PBS. After the agarose gel solidified, samples were 
fixed in position and sheet confocal images were taken at 4x magnification for whole-mount 
samples (3-5μm step size, 6000 images total). After 3D rendering, 100μm-thick samples were 
sliced out to merge into single-plane maximum intensity projection image (none-overlapping 
samples, 4 to 6 different slices from each gel sample, 6 individual implant gels per condition).  
 
4.2.22Ischemic Stroke Model 
G*Power was first used to compute the required sample size. Using two-tailed t-test on 
previous stroke data and high variance assumption for the vessel density measurement, we 
found the required sample size to be within the range of 3 to 9. We used 7 or 8 animals per 
group.  
Animal procedures were performed in accordance with the US National Institutes of 
Health Animal Protection Guidelines and the University of California Los Angeles Chancellor’s 
Animal Research Committee. Focal and permanent cortical stroke was induced by a middle 
cerebral artery occlusion (MCAo) on young adult C57BL/6 male mice (8-12 weeks) obtained 
from Jackson Laboratories. Briefly, under isoflurane anesthesia (2–2.5% in a 70% N2O/30% O2 
mixture), a small craniotomy was performed over the left parietal cortex. One anterior branch of 
the distal middle cerebral artery was then exposed, electrocoagulated and cut. Body 
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temperature was maintained at 36.9 ± 0.4 °C with a heating pad throughout the operation. In 
this model, ischemic cellular damage is localized to somatosensory and motor cortex 125. 
Five days later, HA hydrogel precursor (see Table for composition) was loaded into a 25 
μl Hamilton syringe (Hamilton, Reno, NV) connected to a syringe pump. The solution was then 
injected in liquid form directly into the stroke cavity using a 30-gauge needle at stereotaxic 
coordinates 0.26 mm anterior/posterior (AP), 3 mm medial/lateral (ML), and 1 mm dorsal/ventral 
(DV) with an infusion speed of 1 μl/min. The needle was withdrawn from the mouse brain 
immediately after the injection was complete.  
Table 4.2HA Gel Formula for Ischemic Stroke Model 
HA-ADH-Ac 3.5 wt% 
MMP crosslinker 3.335mM 
Fn9*10 or Fn9(4G)10 or RGD 10μM (FnV) or 500μM (RGD) 
VEGF nanocapsules (nV) or 
soluble VEGF (Vs) 
200ng/6μl Gel 
 
Ten days following the hydrogel transplantation, animals injected with fibronectin 
fragment (Vs+ Fn9*10, nV+Fn9*10 and nV+Fn9(4G)10) containing hydrogels were perfused 
with DyLight 594 labeled Lycopersicon Esculentum (Tomato) Lectin (Vector Laboratories, #DL-
1177) through the left through external jugular vein and then sacrificed by isoflurane overdose. 
Other mice conditions (No gel, HA-RGD and Vs+HA-RGD) were perfused with 4% PFA and 
sacrificed. 
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4.2.23Brain tissue processing 
Mice brains were harvested and post-fixed in 4% PFA overnight or perfused with PFA 
before harvesting, then cryoprotected in 30% sucrose in phosphate buffer for 24 hours and 
frozen. Tangential cortical sections of 30 μm-thick were sliced using a cryostat and directly 
mounted on gelatin-subbed glass slides. Brain sections were then washed in PBS and 
permeabilized and blocked in 0.3% Triton and 10% Normal Donkey Serum before being 
immunohistochemically stained. The primary antibody Rat anti-Ter-119 (R&D Systems, 
#MAB1125, 1:200), Rabbit anti-Glut-1 (Glucose Transporter1, Abcam, 1:400) or Rabbit anti-
Fibronectin (Millipore, AB2040, 1:200) were incubated overnight at +4°C followed by secondary 
antibodies Donkey anti-rat and rabbit- AF488 (Thermo Fisher Scientific, 1:200) for 1 hour at 
room temperature. After 3x 10 minute washes in PBS, the slides were dehydrated in ascending 
ethanol baths, dewaxed in xylene and coverslipped over fluorescent mounting medium (Dako).  
 
4.2.24Microscopy and Morphoanalysis 
Analyses were performed on microscope images of 3 coronal brain levels at +0.80 mm, -
0.80 mm and -1.20 mm according to bregma, which consistently contained the cortical infarct 
area. Each image represents a maximum intensity projection of 10 to 12 Z-stacks, 0.85μm 
apart, captured at a 20x magnification with a Nikon C2 confocal microscope using the NIS 
Element software.  
To quantify the vascular bed in the no gel and gel conditions, Glut-1 stained only or Gut-
1 plus tomato lectin in tomato lectin-perfused animals were quantified. Tomato lectin alters Glut-
1 staining such that in lectin-perfused animals the combination of both stains reveals the 
vascular bed the same as Glut-1 alone in tomato lectin-unperfused animals (Figure 4.13). 
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The vascular area (stained by Glut-1 only or by both tomato lectin and Glut-1) in the 
infarct and peri-infarct areas was quantified in 8 randomly chosen regions of interest (ROI) of 
0.3 mm2 in both regions. In each ROI, the positive area was measured using pixel threshold on 
8-bit converted images (ImageJ v1.43, Bethesda, Maryland, USA) and expressed as the area 
fraction of positive signal per ROI. Values were then averaged across all ROI and sections, and 
expressed as the average positive area per animal. 
The evaluation of perfused vascular ramifications allows for a quantitative analysis 
of the vessel architecture, by counting manually the number of branching points on positively 
tomato lectin perfused vessels of the peri-infarct per mm2. 
 
4.2.25Statistical Analysis 
Statistical analyses were performed using Prism (GraphPad, San Diego, CA). Data were 
analyzed using a one-way analysis of variance (ANOVA) followed by a Tukey post-hoc test and 
a 95% confidence interval. For 2D VE-cadherin staining analysis (n=3) and stroke model 
quantification (minimum n=5), two-tailed unpaired test was used. The results are expressed as 
mean ± SD.  
Single, double, triple and quadruple asterisks represent p < 0.05, p < 0.01, p < 0.001 
and p < 0.0001, respectively. A p value < 0.05 was considered statistically significant. 
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4.3 Results and discussions 
4.3.1 Design and characterization of Integrin-specific 2D surfaces 
 
Figure 4.12D characterizations of Human Umbilical Vascular Endothelial Cells (HUVECs) on Fn9*10 or 
Fn9(4G)10 coated glass bottom cell culture plate or on fragments immobilized heparin-based gold 
surfaces. (a) Immunofluorescence staining of α5β1 and αvβ3 integrin of HUVECs after 18 hours culture in 
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24-well glass bottom cell culture plate which was pre-coated with 500μl of 2 μM Fn9*10 or Fn9(4G)10 
overnight (scale bar 100µm).(b) Similar amounts of immobilized recombinant fibronectin fragments 
Fn9*10 and Fn9(4G)10 on gold surfaces indicated similar reactivity of these two fragments. (c) 
Immunofluorescence staining of αvβ3 integrin, vinculin and PECAM for HUVECs after culturing 24 hours 
on top of fragments immobilized heparin-based gold surfaces (scale bar 50µm). (d) Proliferation study of 
HUVECs after 48 hours of culture on Fn9*10 or Fn9(4G)10 immobilized surfaces with 2ng/ml of VEGF (4 
experiments, 8 wells from each experiment, normalized to control well without VEGF). (e) Migration speed 
analysis of HUVECs on top of Fn9*10 or Fn9(4G)10 immobilized gold surfaces (n=64). **** indicate P < 
0.0001. (f) Migration path of HUVECs (overlapping of 64 individual cell path) on control gold surface, 
control gold surface with 2ng/ml of VEGF, Fn9*10 and Fn9(4G)10 immobilized gold surfaces with 2ng/ml 
of VEGF. 
Fibronectin fragments coated surfaces were first used to verify the specific integrin 
activations on human umbilical endothelial cells (HUVEC). Clear αvβ3 integrin staining was 
observed on Fn9(4G)10 coated surface while signal on Fn9*10 coated surface was low. Also, 
clear β1 integrin staining was observed at cell edge only on Fn9*10 coated surface (Figure 
4.1a). Together, these findings verify the integrin activation specificity for these two fragments. 
To better under the effects of these fragments when they are immobilized, self-assembled 
monolayers on gold were used to specifically immobilize fibronectin fragments and the modified 
surfaces were used for in vitro characterization. Amine containing self-assembled monolayers 
were constructed and used to immobilize malemide-modified heparin via carbodiimide chemistry. 
Fn9*10 and Fn9(4G)10 were subsequently covalently bound using Michael type addition 
between the malemide on the surface and the thiol on the N-terminus of the fibronectin fragment. 
The amounts of attached fragments were then quantified by enzyme-linked immunosorbent 
assay (ELISA) and shown to be the same (~50ng fragment/cm2) for both fragments (Figure 
4.1b), indicating that the reactivity of both fragments is similar. The response of endothelial cells 
(EC) cultured on fragment-modified surfaces was assessed 24 or 48 hours post plating. ECs 
were able to attach and spread on either fragment-modified surface. As expected, only ECs 
seeded on Fn9(4G)10 surfaces showed a positive staining for αvβ3, validating that the fragment 
Fn9*10 does not mediate significant binding through αvβ3. The actin cytoskeleton for cells 
cultured on αvβ3 specific Fn9(4G)10 surfaces showed more short and disoriented actin fibers 
compared with α3/α5β1 specific Fn9*10 surfaces, where actin fibers showed extensive length 
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(Figure 4.1c). This showed that different integrin activation from immobilized fragments impacts 
EC cytoskeleton arrangement on 2D. 
Growth factors are critical for the process of angiogenesis and their incorporation within 
therapeutic angiogenic materials has been a major focus of the field. Here we are interested in 
using vascular endothelial growth factor A 165 (VEGF), which has been described as the 
master regulator of angiogenesis126 , to induce EC sprouting and angiogenesis in vivo. 
Exposure of ECs plated on Fn9*10 or Fn9(4G)10 did not change the binding to αvβ3, which 
remained positive for Fn9(4G)10 but not Fn9*10 (Figure 4.1c). Although no proliferation 
difference was shown for all the conditions tested (Figure 4.1d), EC migration was significantly 
increased for cells cultured on Fn9(4G)10 modified surfaces, which showed induced short and 
disoriented actin alignment(Figure 4.1e,f). Together these findings confirm that ECs alter their 
cellular behavior depending on the integrin binding specificity dominating their attachment to the 
surface.   
 
4.3.2 Integrin stimulation guides endothelial cell sprouting patterns 
Next, we looked at the influence of fibronectin mediated cell adhesion on vascular 
endothelial growth factor A 165 (VEGF) induced vascular sprouting. To study the role of 
fibronectin in EC sprouting, two types of fibrinogen were used, one that contains fibronectin 
(Fib1) and one that is fibronectin and Von Willebrand factor depleted (Fib3). EC coated beads 
were suspended in the fibrin matrices and cultured in the presence of 2ng/ml soluble VEGF for 
7-days following the protocol of Hughes et al127, 128. At day 7, the cultures were fixed, stained for 
actin, and quantified for the number of sprouts, number of branching points and total network 
length per bead.  
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Figure 4.2HUVEC sprouting is great affected by integrin activation from both fibrin matrices with and 
without full length fibronectin (Fn).(a) Representaive immunofluorescent images for Human Umbilical 
Vascular Endothelial Cell (HUVEC) sprouting assay in both Fib1 (fibronectin and von Willebrand Factor 
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containing Fibrinogen)and Fib3 (fibronectin and von Willebrand Factor depleted fibrinogen) fibrin gel with 
no fibronecitn fragment, 2µM Fn9*10 (α3/α5β1 specific matrices) or 2µM Fn9(4G)10 (αvβ3 specific 
matrices). Scale bar: 100 μm. (b,c) Quantification of sprout number and branch points per bead in Fib3 
matrices. (d,e) Quantification of sprout number and branch points per bead in Fib1 matrices (n≥15 
HUVEC coated beads, from 3 independent gels). (f) Representative images and 3D views of HUVEC 
branch structures in both αvβ3 and α3/α5β1 specific Fib3 matrices. Intra-loop and intra-joint branch 
structures were observed in αvβ3 condition (2µM Fn9*10) while organized branch structures were 
observed in α3/α5β1 conditions (2µM Fn9(4G)10). Scale bar: 50 μm. (g) Branch clusters per bead was 
analyzed in Fib3 blank conditions, Fib3+1µM Fn, α3/ α5β1 conditions (2µM Fn9*10) and αvβ3 conditions 
(2µM Fn9(4G)10). (h) Cluster number per sprout was analyzed in Fib3 blank conditions, Fib3+1µM Fn, 
α3/α5β1 conditions (2µM Fn9*10) and αvβ3 conditions (2µM Fn9(4G)10).All plots represent mean ± SD. * 
and ** indicate P < 0.05 and P < 0.01,respectively. 
 
Sprouting and branching points in fibronectin-depleted matrices was significantly 
decreased compared with fibronectin containing matrices, suggesting that the presence of 
native fibronectin is critical for EC sprouting (Figure 4.2a and Figure 4.3a). Addition of 
exogenous fibronectin to fibronectin-depleted matrices partially rescued EC sprouting, resulting 
in statistically increased sprouting, branching points and total network length (Figure 4.3 a); 
however, regardless of the amount of exogenous fibronectin added, the level of sprouting in 
fibronectin-depleted matrices was significantly lower than that observed in fibronectin containing 
matrices(Figure 4.2a and Fgure 4.3a). This indicated that besides the endogenous fibronectin 
within the Fib1 matrices, other factors removed during the Fib3 preparation (e.g. von Willebrand 
factor) may also be important for EC sprouting in fibrin. Among all the tested fibronectin 
concentrations, it was also observed that 1μM was the lowest concentration that achieved 
statistically increased sprouting, branching points and total network length (Figure 4.3a). Thus, 
we decided to incorporate equal molar concentration of Fn fragments, since each fibronectin 
protein presents two copies of Fn III9-10, 2µM of the fragments were used.  
We next tested the role of full length fibronectin, Fn9*10 and Fn9(4G)10 containing 
matrices of EC sprouting. Both the number of sprouts and the branch points per bead showed 
no significant difference among full length fibronectin, α3/α5β1-specific (Fn9*10 fragment added) 
and αvβ3-specific (Fn9(4G)10 fragment added) conditions, indicating that integrin engagement 
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is a major factor that affects the sprouting outcomes (Figure 4.2a-e and Figure 4.3b).Between 
α3/α5β1-specific and αvβ3-specific conditions we observed no differences in sprout number, branch 
points or total network length (Figure 4.2b-e, from three independent gels, and Figure 4.3b-i, comparing 
cross three different days); however, the addition of 9(4G)10 fibronectin fragment (αvβ3-specific specific 
gels) resulted in cluster formation (Figure 4.2a,f). We observed sprouting “clusters” in the αvβ3-
specificmatrices but not on blank, fibronectin, or α3/α5β1-specific matrices (Figure 4.2a,f). The “clusters” 
are merged vessel branch clumps from the same bead, which can either locate close to the surface of the 
beads or on the sprouts. They are always presented as chaotic branch bundles, thus the number of 
branches and sprouts within them are difficult to discern. Using high resolution z-stack confocal imaging 
we found that the clusters were associated with intra-loop and intra-joint structures both within and 
between neighboring sprouts, which were not observed in α3/α5β1-specific matrices (Figure 4.2 f). The 
quantification of the number of branch clusters per bead showed statistically significant occurrence in 
αvβ3-specificgels compared with the blank, fibronectin and α3/α5β1-specific Fib1 or Fib3 matrices from 
both the representative single day experiment with three independent gels and three different day 
experiments treating each day as an independent experiment (Figure 4,2g, Figure 4.3j,k and Figure 4.5a-
c). The quantification of the number of branch clusters per sprout and per branch also showed a similar 
trend (Figure 4.2h and Figure 4.5d-f). These intra-loop and intra-joint features represent chaotic tumor-
like vasculature with over-branched and excessive-shunt vessels129. Taken together, these results 
demonstrate that although both Fn fragments enhanced sprouting and branching of ECs in vitro, they 
lead to different vascular patterns in the resulting EC network. In particular, αvβ3-specificmatrices 
promoted the formation of a pathological vascular network containing intra-loop and intra-joint features. 
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The involvement and importance of integrins in EC sprouting was further confirmed 
through function blocking antibody studies. VEGF induced EC sprouting in α3/α5β1-specific 
matrices in the presence of function blocking antibodies against either α5 or β1 completely 
inhibited the sprouting process to a level lower than observed in fibronectin depleted matrices. 
In contrast, EC sprouting in αvβ3-specific matrices in the presence of function blocking 
antibodies against αv did not impact sprouting, while function blocking antibodies against β3 
again completely inhibited the sprouting process. These results indicate that α5, β3, and β1 are 
essential to EC sprouting but αv is not (P3G8 antibody concentration was optimized using flow 
cytometry in Figure 4.5g,h), further illustrating the importance of integrin binding to biomaterials 
to promote angiogenesis (Figure 4.4a and Figure 4.5i,j). We next explored whether blocking αv 
normalized the resulting vasculature by decreasing the number of intra-loop and intra-joint 
structures. Surprisingly, blocking αv binding significantly decreased the number of branch 
clusters (Figure 4.4b), suggesting that αv binding is responsible for the sprout clusters formed in 
the αvβ3-specific matrices. These results are in agreement with previous studies showing that 
activation of αvβ3 results in increased  vascular permeability in 2D26 while inhibition of αv 
reduces vascular permeability130.  
Figure 4.3(a) Human Umbilical Vascular Endothelial Cell (HUVEC) sprouting assays were perfomed 
within both Fib1( Fn and Von Willebrand Factor containing Fibrinogen) and Fib3( Fn depleted 
Fibrongen) matrices. Different amounts of exogenous of Fn were added to Fib3 to understand the 
effects of fibronectin on spouting process. Total network length per bead including all sprouts and 
branches was shown here (n>=15, from 3 independent gels). (b) Quantification of total network length 
per bead in Fib3 matrices. (c) Quantification of total network length per bead in Fib1 matrices. (d-f) The 
Fib3 (fibronectin-depleted) fibrin sprouting assay were repeated three times on different days. 
Normalized quantification of sprout number, branch points and total network length per bead with all 
three experiments were shown here. n=3, each day considered as one sample. (g-i) The Fib1 fibrin 
sprouting assay were repeated three times on different days. Normalized quantification of sprout 
number, branch points and total network length per bead with all three experiments were shown here. 
n=3, each day considered as one sample. (j) Quantification of cluster occurance per bead in Fib3 
(fibronectin-depleted) fibrin matrices with three repeated experiments in different days were shown 
here. n=3, each day considered as one biological replicate. (k) Quantification of cluster occurance per 
bead in Fib1 fibrin matrices with three repeated experiments in different days were shown here. n=3, 
each experiment considered as one sample. *,**,*** and **** indicate P < 0.05, P < 0.01, P < 0.001 and 
P < 0.0001, respectively. 
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Figure 4.4 Intra-joint and intra-loop strucutre exist in matrices dosed with 9(4G)10 and RGD. (a) 
Microscopic analysis of whole bead sprouting outcomes (scale bar: 100 μm) and intra-joint and intra-loop 
branch structures (scale bar: 50 μm) from the blockage of integrin αv, α5, β1 or β3 (5µg/ml) of 2 µM 
Fn9*10 or 2 µM Fn9(4G)10 added Fib1 gels. (b) Branch cluster occurance comparison between 2 µM 
Fn9(4G)10 Fib1 gels with and without αv blocking (n=51 HUVEC coated beads from three independent 
gels). (c,d) Sprout number per bead and branch points per bead were quantified in 0,200,500 and 1000 
µM RGD added Fib3 matrices (n≥15 HUVEC coated beads, from 3 independent gels). (e) Representative 
image of intra-loop and intra-joints structures in Fib3 matrices with 1000µM RGD added. Scale bar: 50 
μm. (f)Branch cluster occurance per bead were quantified in 0,200,500 and 1000 µM RGD added Fib3 
matrices.All plots represent mean ± SD. *,**,*** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 
0.0001, respectively. 
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Figure 4.5(a,b) Average 
branch cluster per bead and 
branch cluster distribution 
were analyzed for blank, 
α3/α5β1 specific (2µM 
Fn9*10) and αvβ3 specific 
(2µM Fn9(4G)10) Fib1 
matrices. (c) Branch cluster 
distribution was analyzed 
for blank, 1µM Fn added, 
α3/α5β1 specific (2µM 
Fn9*10) and αvβ3 specific 
(2µM Fn9(4G)10) Fib3 
matrices. (d,e) Cluster 
number per sprout  and 
cluster number per branch 
were analyzed in blank, 
α3/α5β1 specific (2µM 
Fn9*10) and αvβ3 specific 
(2µM Fn9(4G)10) Fib1 
conditions. (f) Cluster 
number per branch were 
analyzed in blank, 1µM Fn 
added, α3/α5β1 specific 
(2µM Fn9*10) and αvβ3 
specific (2µM Fn9(4G)10) 
Fib3 conditions. (g,h) FACS 
analysis of the efficiency of 
αv blocking functional 
antibody P3G8. 1µg/ml of 
P3G8 in 100ul of media was 
shown to effectively bind to 
more than 95% of αv 
integrin on 60,000 HUVECs. 
(i,j) Microscopic analysis of 
whole bead sprouting 
outcomes (scale bar: 100 
μm) from the blockage of 
integrin αv, α5, β1 or β3 
(5µg/ml, replenished every 
2 days) on 0.267 µM 
Fn9*10 or 0.239 µM 
Fn9(4G)10 dosed Fib1 and 
Fib3 matrices.  (k,l) 
Microscopic analysis and 
quantification for total 
network length in 0,200,500 
and 1000 µM RGD modified 
Fib3 matrices.*,*** and **** 
indicate P < 0.05, P < 0.001  
and P < 0.0001, 
respectively. 
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4.3.3 Matrices modified with RGD peptides show similar vascular pattern as Fn9(4G)10 
Next, we sought to examine vascular patterns utilizing the ubiquitously used synthetic 
peptide derived from fibronectin, RGD. RGD peptides with α2PI1-8 sequences (H-
NQEQVSPLRGDSPG-NH2) were incorporated within fibrin matrices using the same FXIIIa 
chemistry used for the incorporation of our fibronectin fragments. As observed with the 
fibronectin fragments, the incorporation of RGD within Fib3 matrices resulted in enhanced EC 
sprouting (Figure 4.4c,d and Figure 4.5k,l). Similar intra-loop and intra-joint structures were 
found in RGD modified fibrin matrices (Figure 4.4e) and the number of clusters were statistically 
increased for matrices containing 1000µM RGD peptide (Figure 4.4f). These results suggest 
that RGD binding without the presence of the proline-histidine-serine-arginine-asparagine 
(PHSRN) “synergy” domain on the 9th type III repeat131, 132, result in pathological angiogenesis, 
which may come from the preferential αvβ3 binding133. It should be noted that the effect of 
enhanced sprouting and disorganized structures was only observed for a much higher 
concentration of RGD peptide (> 500µM) compared with the concentration of fibronectin 
fragments used (2µM); this result confirms that fibronectin fragments more efficiently display the 
RGD motif to cells resulting in more efficient binding.  
Upregulation of αvβ3 and alterations in its activation state has been associated with 
disease states such as cancer 27, 134, 135 and fibrosis 136, 137 and has been widely used as a 
cancer targeting ligand in drug delivery applications 138, 139, yet RGD is the most widely used 
integrin binding peptide to modify biomaterials. Our results show a dose dependent effect of 
RGD on vascular patterning with increasing doses leading to increased pathological vessels 
resulting in sprouting vessel clusters. We do not mean to suggest that the use of RGD modified 
biomaterials for therapeutic angiogenesis is inherently flawed; rather, we believe that the 
incorporation conditions for RGD peptides such as presentation, concentration, and other 
neighboring ligands should be studied to ensure that the desired revascularization pattern is 
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obtained. For example, clustering RGD within hydrogels has been shown to upregulate the 
expression of β1 integrin 105 and immobilization of VEGF leads to β1 recruitment 99.  
 
4.3.4 Integrin stimulation guides vascular anastomosis 
Vessel anastomosis is a crucial step in vasculature renewal and repair, guiding the 
fusion of adjacent vessel branches. In healthy vessels, once a vessel branch is formed, the 
majority of endothelial cells become quiescent, among which only 0.01% still divide 140. During 
the angiogenesis process, sprouts from parental vessels fuse with other sprouts or pre-existing 
blood vessels for the purposes of supplying blood and oxygen to surrounding tissues 141-143. This 
anastomosis process not only affects vascular network distribution, but also has great impacts 
on structure, quality and maturation of newly formed vessels. To test the effect of αvβ3 and 
α3/α5β1 on EC sprout anastomosis, a similar bead assay was performed using stably 
transfected ECs expressing enhanced green fluorescent protein (EGFP). HDFs were seeded 
within the fibrin matrix to yield more robust and long-lasting tubes for longer culture.  EC sprouts 
were monitored daily and analyzed at day 11 when anastomosis between adjacent beads 
started. Normal anastomosis results in the binding of tip cells through a single tip cell contact 144. 
Clear single tip-tip contact or paralleled tip interaction were observed in both blank and α3/α5β1 
specific (Fn9*10 added) conditions (Figure 4.6a-f), indicating that further inducing α3/α5β1 
integrin engagement supports similar anastomosis as native fibronectin present in the Fib1 
matrix. In contrast, αvβ3 integrin engagement through Fn9(4G)10 modified matrices promoted 
multiple tip-tip contacts, resulting in independent contact sites and loop structures (Figure 4.6g-j). 
Thus, consistent with our observations in EC sprouting morphogenesis, inter-loop and inter-joint 
structures are observed in anastomosed sprouts within αvβ3-specificmatrices. 
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Figure 4.6Microscopic analysis of anastomosis process of EGFP-HUVEC sprouts at day 11. (a,d,g) Inter-
beads branch overview of blank, 2 µM Fn9*10 (α3/α5β1 specific) and 2 µM Fn9(4G)10 (αvβ3 specific) 
Fib3 gels. Scale bar: 200 μm. (b,e,h) Sample 1 of bead-bead tip cell interactions. Scale bar: 100 μm. 
(c,f,i) Sample 2 of bead-bead tip cell interactions. Scale bar: 100 μm. (j) Different tip-tip contact 
distribution within the 170μm of working distance of 60x objective. 
 
4.3.5 αv activation leads to pathological vasculature through VE-cadherin disruption 
Next, we investigated possible mechanisms for the observed differences in the vascular 
patterns generated by α3/α5β1-specificand αvβ3-specificmatrices.  Failure to generate single 
tip-tip contact sites during anastomosis with αvβ3-specificmodified matrices suggested 
disturbed polarization events between interacting tip cells and disrupted VE-cadherin signaling 
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144. VE-cadherin is known to be necessary for the generation of a single polarization event 
between interacting tip cells 144. Vessel sprouts lacking VE-cadherin display irregular 
anastomosis, characterized by multiple tip-tip contact sites and disturbed junctional connections 
144, similar to our observations in Fn9(4G)10 condition. As an important cell-cell junction protein, 
Figure 4.7VE-cadherin disuption was observed on αvβ3 specific 2D surface and in 3D fibrin matrices. 
(a) Microscopic analysis of 2D VE-cadherin distribution onα3/α5β1 or αvβ3specific surfaces without 
VEGF dosage after 12 hours. Scale bar: 50 μm. ** indicate P < 0.01. (b) Quantification of VE-Cadherin 
to nuclei area ratio for HUVECs on α3/α5β1 or αvβ3specific surfaces without VEGF dosage after 18 
hours.(c) Grey value distribution analysis for 3 random cell-cell junctions onα3/α5β1specific surface 
from (a). (d) Grey value distribution analysis for 3 random cell-cell junctions onαvβ3specific surface 
from (a). (e) Microscopic analysis of VE-cadherin signals from blockage of αv integrin on αvβ3specific 
Fib1 matrices (2µM Fn9(4G)10) in comparison to α3/α5β1 specific matrices. Scale bar: 100 μm (whole 
bead) and 50 μm (sprouts). 
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VE-cadherin is not only responsible for shifting endothelial cell response to VEGF from 
proliferation and migration to survival and quiescence 145, but also functions to maintain low 
permeability of endothelial cell layer 26. Even partial knockout of VE-cadherin can lead to 
vascular instability and hemorrhages146. Most importantly, VE-cadherin function can be 
disrupted by upregulation of αvβ3 integrin, enhancing endothelial cell permeability26. Thus, we 
hypothesize that αvβ3 activating scaffolds lead to pathological intra-vessel and inter-vessel 
features through VE-cadherin disruption.To verify our hypothesis, we first examined VE-
cadherin distribution on EC cultured in vitro on αvβ3 or α3/α5β1 specific surfaces. After 18 
hours, cells seeded on α3/α5β1 specific surface showed significantly increased amount of VE-
cadherin signal at cell-cell junctions compared with αvβ3 specific condition both without and with 
VEGF presence (Figure 4.7a and Figure 4.8a). Obvious absence and significantly lowered VE-
cadherin signals between adjacent cells were observed on αvβ3 specificsurfaces, indicating VE-
cadherin disruption (Figure 4.7a,b and Figure 4.8a). VE-cadherin grey value analysis was 
performed on randomly-chosen cell-cell junctions from Figure 4.7a. It was observed that 
α3/α5β1 specific surface led to wider VE-cadherin layer with stronger signal at cell-cell junction 
when compared with αvβ3 specific surfaces (Figure 4.7c,d). EC sprouting in αvβ3 
specificmatrices was also characterized by reduced VE-cadherin staining (missing VE-cadherin 
staining is labeled using the arrow) on sprout shunts and cell-cell junctions compared with EC 
sprouting in α3/α5β1 specific matrices (Figure 4.7e,f). To confirm that increased αv integrin 
binding is responsible for the decrease in VE-cadherin staining, αv integrin binding was 
disrupted using function-blocking antibodies. VE-cadherin staining after αv blocking in αvβ3 
specific fibrin matrices showed EC cells with increased VE-cadherin staining (clear VE-cadherin 
staining is labeled by star) similar to what was observed in α3/α5β1 specific matrices, indicating 
that αv binding is responsible for the reduction in VE-cadherin expression. The effect of αv 
blocking was observed in both Fib1 and Fib3 matrices (Figure 4.7e and Figure 8b,c). Taken 
together, these findings support our hypothesis that VE-cadherin-related pathological 
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vasculature was caused by αv activation and demonstrate that αv blockage can be utilized to 
rescue the pathological effects. 
 
 
Figure 4.8VE-cadherin disuption was observed on αvβ3 specific 2D surface with presence of VEGF and 
also in 3D fibrin matrices. (a) Microscopic analysis and quantification of 2D VE-cadherin distribution on 
fragment coated cell culture dish with 2ng/ml VEGF dosage at 12 hour time point. Scale bar: 50μm. .*** 
indicate P < 0.001. (b) Microscopic analysis of VE-cadherin signals from blockage of αv integrin on 
0.239µM Fn9(4G)10 added Fib1 gels in comparison to 0.267µM Fn9*10 added Fib1 gels. (c) Microscopic 
analysis of VE-cadherin signals from blockage of αv integrin on 0.239µM Fn9(4G)10 added Fib3 gels in 
comparison to 0.267µM added Fn9*10 Fib3 gels. 
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4.3.6 Integrin stimulation from a bioengineered matrix guides vascular patterns in vivo 
 
Figure 4.9 (a-d) The workflow of modified matrigel plug assay. (e) Scheme for synthesising 100% L, 75% 
L, 50% L and 25% L protease-sensitive VEGF nanocapsules. (g) Scheme for implanted MMP-crosslinked 
HA Hydrogels containing fibronectin fragments (Fn9*10 or Fn9(4G)10) and equal amount of each type of 
VEGF nanocapsules. The HA hydrogles were also labeled with AF555 for visualization purposes.(f) 
Fluorescent analysis of D1 cell spreading after 2 days in HA hydrogels with 1, 5, 10, 20, 50µM of Fn9*10 
dosage. 10µM fragment induced the most cell spreading without little apoptosis. (h) Optimization of 
storage modulus for the HA implant hydrogel by varying R ratio (crosslinker thiols to maleimide ratio). 
The fibronectin fragments were also tested in a modified matrigel plug assay that uses 
bioengineered hyaluronic acid (HA) hydrogels instead of matrigel to assess angiogenesis in 
mice (Figure 4.9a-d). HA hydrogel is chosen for our studies because it does not interact with 
cells through integrin receptors and provides a clean system to study integrin-mediated events. 
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HA hydrogel has been injected in vivo, has been shown to support delivery of biocues and is 
also currently used under clinical settings. HA hydrogels are formed through crosslinking HA 
molecules using Michael type addition chemistry between acrylamide groups introduced to the 
backbone of hyaluronic acid and dithiol crosslinker containing protease degradable peptides147. 
Fn fragments were also introduced to this protease degradable hydrogel matrix backbone to 
mediate integrin binding using the same Michael type chemistry through the cysteine in the 
fragment N-terminus. VEGF was incorporated into the system using a controlled release system 
based on single protein nanocapsules previously developed in our laboratory 148, 149. 
Nanocapsules are formed through in situ radical polymerization of acrylate and acrylamide 
containing monomers and peptide crosslinkers around a protein core (Figure 4.9e). The final 
product is a protein complex in which the protein is surrounded by a hydrated protease-
degradable polymeric shell. By changing the amino acids in the peptide crosslinker from L 
enantiomer to D enantiomer, the kinetics of enzymatic cleavage are modulated to control the 
release rate of VEGF over time. We have previously shown that by mixing fast and slow 
degrading nanocapsules we can achieve a release rate that can promote vascularization in skin 
and brain leading to enhanced wound closure 148, 150. Here we utilized nanocapsules crosslinked 
by the plasmin-degradable peptide KNRVK. We synthesized four different VEGF nanocapsules 
containing 100% L, 75% L, 50% L or 25% L crosslinker (Figure 4.9e) and mixed them at equal 
amounts to achieve sustained VEGF release. Hydrogels containing none or 10µM fibronectin 
fragments (this amount has been shown to sufficiently promote cell spreading in HA hydrogel in 
vitro, Figure 4.9f), 200ng VEGF nanocapsules, and having a storage modulus of 350Pa were 
implanted subcutaneously (Figure 4.9g,h). Evaluation of isolectin perfused whole mount 
sections was performed 14-days after implantation on light sheet microscopy (Figure 4.10a) and 
confocal microscopy. HA hydrogels that do not contain fibronectin fragments (blk) resulted in the 
least vessel sprouting on the hydrogel surface and vessel infiltration within the hydrogel 
compared with fragment conditions even with the presence of VEGF nanocapsules, 
 74 
demonstrating that integrin binding is essential for angiogenesis to occur in vivo (Figure 4.10b). 
HA hydrogels modified with either fibronectin fragment supported an angiogenic response; 
however, the morphology of the vessels on the gel surfaces was significantly different. The 
α3/α5β1 specific HA gels (Fn9*10 immobilized) displayed non-tortuous vessels displaying 
similar features as the normal mouse vasculature (control) while αvβ3 specificgelsdisplayed 
tortuous and unorganized vessels that appeared to clump with one another (Figure 4.11a-c). 
Also, vessel distribution analysis also indicated a more space-filling vasculature on α5β1 
specific gel surface compared with αvβ3-specific gels (Figure 4.11d). While vessels on α5β1 
specific gel surfaces presented organized and even vessel distribution like the blank gel control, 
vessels on αvβ3 specific gel surfaces yields uneven distribution, which originated from regional 
tortuous and unorganized vessel clumps (Figure 4.11d).  
Next, light sheet fluorescent microscopy was used for large-scale whole-mount gel scan 
(approximately 8mm in diameter, 3mm in thickness) in order to evaluate the penetration of 
vessels (Figure 4.10a,b). Through the 3D heat map view, we were able to visualize vessel 
penetration starting from the gel surface (Figure 4.10c). Projection view was later acquired via 
dividing whole-scanned 3D gel structure into 100um thickness slices and performing maximum 
intensity projection. This helped us visualize the penetrating vessels. As expected, clear vessel 
infiltration was observed in both α3/α5β1 specificand αvβ3-specificgels (Figure 4.10d). 
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Figure 4.10 (a) Schematic for light sheet microscopy detection system. (b) Bulk 3D visualization of 
isolectin-labeled vessel on the surface and inside of blank, α3/α5β1 specific, αvβ3 specific HA matrices 
(labeled as blue) after 14 days in vivo. (c) Zoom-in 3D heat map for vessel penetration visualization (HA 
matrices were labeled as blue). (d) Projection view for vessel penetration within blank, α3/α5β1 specific 
and αvβ3 specific matrices after 2 weeks in vivo. Scale bar: 100 μm. 
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Figure 4.11A modified matrigel plug assay using bioengineered hyaluronic acid (HA) hydrogels is utilized 
to assess angiogenesis in mice. (a) Comparison of normal mice skin vessel morphologies with the 
morphologies of infiltrated vessels on the surfaces of implanted blank, α3/α5β1 specific (10µM Fn9*10) 
and αvβ3 specific (10µM Fn9*10) HA hdyrogels with VEGF nanocapsules (200ng per gel) 2 weeks after 
implantation. Scale bar: 200 μm. (b) Representative 40x images of vessels on the surface of α3/α5β1 
specific and αvβ3 specific HA matrices. Scale bar: 50 μm. (c) Vessel totuosity comparison among blank, 
α3/α5β1 specific and αvβ3 specific conditions (n = 4 individual implants). (d) Heat map ananlysis of 
vessel distribution on the surfaces of blank, α3/α5β1 specific and αvβ3 specific matrices (n=4 individual 
implants). Darker box indicates higher vessel density in that region while white indicates the absence of 
vessels. Plot represents mean ± SD.** indicate P < 0.01. 
 
4.3.7 α3/α5β1 integrin binding reduces VEGF induced vascular permeability after stroke 
VEGF is the key regulator of angiogenesis and it has been widely investigated in clinical 
and preclinical models to promote perfusion in various organ systems 151-154. However, VEGF 
has been plagued with negative clinical trials showing little therapeutic benefit at safe doses 155-
158 and the generation of a leaky and immature vasculature 159, 160. Thus, effective VEGF 
delivery is a holy grail in the field of therapeutic angiogenesis. In the brain, VEGF is one of the 
essential molecules in normal post-stroke angiogenesis 161; however, the delivery of VEGF after 
stroke has been complicated by the induction of a disordered and permeable vasculature 162, 163. 
Thus, we next sought to evaluate the angiogenic response of integrin stimulation on VEGF-
induced angiogenesis in a murine model of brain stroke. Staining of stroke site has revealed 
increased expression of ECM protein such as fibronectin (Figure 4.12a and Figure 4.13a).  We 
believe that by utilizing integrin specific implants, the micro-ECM environment at the stroke site 
could be  modulated to promote therapeutic outcomes. Adult mice were submitted to a cerebral 
artery occlusion (MCAo) and transplanted 5 days later with a 350Pa HA-RGD hydrogel 
containing 200ng of VEGF nanocapsules and 10µM fibronectin fragments (nV+Fn9(4G)10 and 
nV+Fn9*10 directly into the stroke cavity (Figure 4.12b). Animal control groups were 
transplanted with either HA-RGD hydrogel alone (RGD), HA hydrogel containing soluble VEGF 
and RGD (Vs+RGD) or the star fragment (Vs+ Fn9*10) or nothing (No gel). Ten days post-
transplantation, animals injected with fibronectin fragment containing hydrogels were perfused 
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with tomato lectin before sacrifice for the purpose of studying perfused vessel morphology while 
other animals were directly perfused with 4% PFA and sacrificed. 
Sections were all stained for Glut-1, a glucose transporter expressed on brain 
endothelial cells and the positively stained vascular area was quantified in both the infarct and 
peri-infarct areas (Figure 4.12c). To compare the vascular bed in all conditions, both Glut-1 
stained only and Gut-1 plus tomato lectin stained in tomato lectin-perfused animals were 
quantified. Glut-1 stained for all vessels while tomato lectin only stained for perfused vessels. 
Tomato lectin alters Glut-1 staining such that in tomato lectin-perfused animals the combination 
of both stains reveals the vascular bed the same as Glut-1 alone in tomato lectin-unperfused 
animals (Figure 4.13b). As expected, all the VEGF containing hydrogels showed a greater 
vasculature area percentage than RGD only gels in the infarct and the peri-infarct regions. 
However, we found that the vascular area was significantly increased in the nV+star (α3/α5β1 
specific) condition compared with any other group in both regions (Figure 4.12d, e), suggesting 
a strong role of activated α3/α5β1 integrin binding in promoting the angiogenesis process. The 
significantly increased vessel area percentage of nV+ Fn9*10 when comparing with Vs+ Fn9*10 
condition in both areas also verified the greater therapeutic effects from VEGF nanocapsules. 
In order to evaluate the quality of these newly formed vascular network, both their 
permeability and structure were studied. For this, Ter-119, a red blood cell marker, was 
fluorescently stained and quantified in terms of positive area in the stroke regions (Figure 4.12c). 
The results showed a significantly reduced positive area for Ter-119 in the nV+ Fn9*10 
condition compared with the nV+Fn9(4G)10 group, suggesting a beneficial effect of the 
activation of α3/α5β1 in promoting vascular permeability and stability while reducing blood 
leakage (Figure 4.12f). In addition, the morphoanalysis of tomato lectin-perfused vessels was 
performed by quantifying the number of vascular ramification growing out of a common vascular 
tree (Figure 4.12b). We found that the number of ramification per mm2 was significantly greater 
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in the nV+star condition compared with the nV+4G group, indicating that stimulating α3/α5β1 
integrin activation also promotes the formation of a physiological vascular architecture around 
stroke site (Figure 4.12g).  
These results demonstrate for the first time that the therapeutic effect of VEGF on post-
stroke angiogenesis can be regulated by the specific integrin stimulation, influencing not only 
the intensity of the vascular growth but also its vascular patterning and quality.  
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Figure 4.12An middle cerebral atery occlusion (MCAo) ischemic stroke model was utilized to look at the 
effects of injected integrin-specific HA matrices on stroke repair 10 days post-injection (injection was 
performed 5 days post stroke). (a) Fibronectin(Fn) immunofluorescence staining on stroke site and 
cotralateral side of mouse brain 15 days post stroke showed enhanced Fn signals around stroke site. (b) 
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Schematic illustration of mouse brain coronal sections showing a cortical stroke and the transplantation of 
an injectable hyaluronic acid (HA) hydrogel within the damaged area represented by the asterisk. In order 
to protect the healthy parenchyma from nearby lesion area, star-shaped glial cells, astrocytes, elongate 
and surround the damaged site, forming the astrocytic scar. This stroke cavity is situated directly adjacent 
to the region of the brain that undergoes the most substantial repair and recovery, the peri-infarct tissue, 
where new structures such as vessels develop and infiltrate the infarct while undergoing a drastic 
remodeling process. The growing vasculature structure and permeability are both associated with tissue 
repair.  (c) Fluorescent microscopy showing brain vasculature in both the infarct and peri-infarct (stained 
for Glut-1 or Glut-1 plus tomato lectin intravascular perfusion) as well as leaked red blood cells (stained 
for Ter-119) in the no gel, 500μM RGD , 200ng soluble VEGF(Vs) + 500μM RGD, 200 ng Vs+ 10 μM 
9*10, 200ng VEGF nanocapusules (nV) + 10μM 9(4G)10 and 200ng nV + 10μM 9*10 conditions. VEGF 
nanocapsules were designed to slowly release VEGF. Scale bar: 100 μm. (d,e) The results showed a 
significantly increased positive area for stained vessels in both the infarct and the per-infarct areas of 
nV+star transplanted mice compared with any other group. ** and *** indicate P < 0.01 and P < 0.001, 
respectively. (f) The measure of Ter-119 positive red blood cells in the two nV conditions show a 
significantly reduced area in the infarct site of nV+star (α3/α5β1 specific matrices) transplanted mice 
compared with nV+4G (αvβ3 specific matrices). This result shows that nV+star decreased leakiness of 
growing vessels in the stroke brain. *  indicates P < 0.05. (g) The morphoanalysis of growing vessels in 
the peri-infarct area shows a significantly increased number of vascular ramifications in the nV+star 
condition compared with the nV+4G, suggesting that nV+star promotes a post-stoke vascular remodeling 
into a more physiological network. All plots represent mean ± SD. *  indicates P < 0.05. 
 
Figure 4.13 (a) Non-stained control and non-primary antibody control of Fibronectin(Fn) 
immunofluorescence staining on stroke site and cotralateral hemisphere of mouse brain 15 days post 
stroke. (b) Data presented here showed positively stained vessels of the contralateral hemisphere in both 
Glut-1 stained conditions or Glut1 plus tomato lectin perfused conditions. No significant difference was 
shown on positive vascular area percentage and vessel morphology between these two conditions. Scale 
bar: 100 μm. 
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4.4 Conclusions 
Integrin binding to bioengineered hydrogel scaffolds is essential for tissue regrowth and 
regeneration, yet not all integrin binding can lead to tissue repair. Vascular endothelial growth 
factor (VEGF) is known as the master regulator of angiogenesis. It contributes to vascular 
permeability at early stages of wound healing, promotes effective granulation formation and also 
correlates with scar tissue formation at the final stages of wound healing. Acute tissue damage 
such as brain stroke requires the formation of a mature and organized vasculature induced by 
VEGF to initiate the recruitment of pro-repair cells and promote tissue regeneration. The 
vascular remodeling that follows the initial growth is essential for the newly formed vessels, 
initially permeable and tortuous, to mature into a functional network that can support tissue 
repair. Here we show that through engineering hydrogel materials to promote α3/α5β1 integrin 
binding with VEGF presence, we can promote the formation of a space filling and mature 
vasculature compared to hydrogel materials that promote a αvβ3 integrin binding. In vitro, 
α3/α5β1 scaffolds promoted endothelial cells to sprout and branch, forming organized extensive 
networks that eventually reached and anastomosed with neighboring branches. In vivo, α3/α5β1 
scaffolds delivering vascular VEGF promoted non-tortuous blood vessel infiltration and non-
leaky blood vessels by 10 days post stroke. In contrast, materials that promote αvβ3 integrin 
binding promoted endothelial sprout clumping in vitro and leaky vessels in vivo. This work 
shows that precisely controlled integrin activation from a biomaterial can be harnessed to direct 
therapeutic vessel regeneration and reduce VEGF induced vascular permeability in vivo(Figure 
4.14). 
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Figure 4.14Summary figure for in vitro sprouting assay, in vivo subcutaneous modified matrigel assay and 
in vivo ischemic stroke model. In conclusion, α3/α5β1 and αvβ3 integrin-specific materials regulate 
angiogenesis process differently both in vitro and in vivo. α3/α5β1 specific materials affects vascular 
patterning in vivo by reducing vessel tortuosity and also promoting the development and maturation of 
newly formed vessels in the damaged brain, thus representing a promising candidate in the design of 
therapeutic pro-angiogenic scaffolds. 
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Integrin binding is a fundamental design parameter for engineering matrices for tissue 
repair and regeneration. The incorporation of integrin binding molecules within engineered 
matrices ranges from peptides such as RGD117, to protein fragments118, and natural proteins119, 
with the primary purpose to promote cell spreading and migration within these matrices. 
However, integrin binding ligands are often overlooked as bioactive cues, capable of dictating 
morphogenesis and guiding tissue repair. Our work shows that integrin stimulation from 
engineered matrices is a morphogenic signal that can be harnessed to generate either a normal 
vasculature or a diseased vasculature depending on the integrin being engaged (Figure 4.14).In 
the work presented here, we establish an integrin-specific material platform via the 
immobilization of fibronectin derived protein fragments to fibrin or hyaluronic acid matrices to 
induce specific α3/α5β1 or αvβ3 integrin activation. We found that α3/α5β1 and αvβ3 integrin-
specific materials regulate vascular patterning. αvβ3 integrin-specific materials lead to 
pathological tumor-like sprouting clumps, which can later be rescued by the blockage of αv 
integrin. α3/α5β1 integrin-specific materials lead to a space filling vasculature that has reduced 
vessel tortuosity and promotes the development and maturation of newly formed vessels in the 
damaged brain, thus representing a promising candidate in the design of therapeutic pro-
angiogenic scaffolds. 
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Chapter 5  
VEGF clusters improve diabetic skin wound healing 
 
 
5.1 Introduction 
An estimated 3 to 6 million chronic skin ulcers occur in patients every year in the United 
States164, 165, among which, diabetic foot ulcers (DFUs) have become one of the most common 
and severe complications of diabetes. It is known that DFUs are now the leading cause for 
hospitalization in patients with diabetes and also the presence of an ulcer may increase the risk 
of lower-extremity amputation by almost six folds, affecting Diabetic patients’ quality of lives, 
hospital stay and survival rate166-169. The severity of DFUs is due to the impairment of numerous 
components of wound healing in diabetic patients170, including hemostasis and inflammation, 
matrix deposition, and angiogenesis. These impairments are present in a wide variety of tissues 
including myocardium, skeletal muscle, nerve, and skin. Specifically, cutaneous wounds in 
diabetics have exhibited altered blood flow, impaired neutrophil anti-microbial activity, and also 
dysfunctional inflammatory state associated with abnormal chemokine expression171. Compared 
with healing through contraction, as occurs in normal wounds, diabetic wounds tend to heal by 
cellular infiltration, deposition of granulation tissue, and re-epithelialization. This process is 
common to the healing of chronic ulcers in patients with diabetes decubitus ulcers, and venous 
stasis172.  
As the master regulator of angiogenesis, Vascular endothelial growth factor (VEGF) is 
not only crucial for vascular development during embryogenesis173, 174, but also is required for 
the homeostasis of blood vessels in adult175. Increasing evidence suggest that the relatively low 
level of VEGF in diabetic wounds is responsible for the impaired healing process in these 
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patients176. While the basal level of VEGF is increased in un-wounded skin of db/db mice, the 
VEGF level comes with a significant delay after wounds occur. In full-thickness diabetic 
excisional wound, VEGF levels initially increase but eventually decrease to undetectable levels 
by day 5. In comparison, VEGF peaks in nondiabetic normal tissue and granulation tissue is 
accumulating at the same time points177. Thus,VEGF is a potential agent that helps promoting 
diabetic wound healing.  
However, as a paracrine endothelial cell mitogen, a chemotactic agent, and an inducer 
of both vascular and skin permeability178-182, VEGF has been plagued with negative clinical trials 
showing little therapeutic benefit at safe doses 155-158 and the generation of a leaky and 
immature vasculature 159, 160. Topical VEGF application (20µg every other day) on db/db 
cutaneous wounds showed accelerate wound healing despite the induction of disordered 
vasculature170. Clinical trials have also been performed using topical recombinant human VEGF 
on diabetic foot ulcers; however, even though positive trends such as epithelialization 
stimulation and collagen production were seen, no published information is available beyond 
these phase I studies183.  
Despite the fact that soluble VEGF alone doesn’t result in a healthy vascular network 
formation and requires microenvironment dosage control184, experimental studies have shown 
that sustained74, immobilized VEGF promotes angiogenesis and the formation of healthy 
vessels 44, 185. Thus, it is crucial to utilize different presentation of VEGF to promote diabetic 
wound healing. Our lab previously showed that VEGF clusters with polystyrene bead core 
increased endothelial tube branch points compared with covalently-linked VEGF and soluble 
VEGF106. Based on the previous work, two different types of new heparin-based VEGF clusters, 
highly clustered VEGF (hcV) and lowly clustered VEGF (lcV) were synthesized and applied on 
diabetic cutaneous wounds with one-time small dosage (200ng per wound). Highly clustered 
VEGF (hcV) were shown to effectively reduce wound size, encourage re-epithelization and 
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promote endothelial cell/pericyte recruitment after 7 days while lcV didn’t. This present work 
shows that small dosage of highly clustered VEGF can be utilized as an effective agent to 
promote diabetic cutaneous wound healing. 
5.2 Materials and methods 
5.2.1 Synthesis of VEGF clusters 
Heparin was first modified with p-azidobenzyl hydrazide (ABH, Pierce, Rockford, IL) 
through EDC mediated conjugation in a 1:3 molar ratio of ABH to available carboxylic acids. The 
pH was monitored during the course of the reaction and the conjugation took place at pH 4.75 in 
PBS. After 2 h of reaction at room temperature, the carboxylic acid groups on heparin were 
reactivated with EDC, but this time reacted with adipic dihydrazide (ADH) in 27 molar excess in 
order to saturate reaction binding sites and prevent unwanted crosslinking. Again, the reaction 
pH was monitored at pH 4.75 in PBS. This reaction was allowed to proceed overnight at room 
temperature, at which point the reaction solution was dialyzed against DI water. The dialysis 
units were then placed in PBS at pH 7.4 for buffer exchange. Heparin with ABH and ADH was 
then reacted with NHS-acrylate to convert the amine groups to acrylates. The reaction 
proceeded overnight at room temperature, and then dialyzed again. After dialysis, the solution 
was lyophilized for two days. The powder was dissolved in sodium acetate, pH 4, at 100 mg/ml 
and combined with Tween-80 and Span-80 (8% HLB). The solution was placed in a ten-fold 
volume of hexane and combined with N,N,N’,N’-tetramethyl-ethane-1,2-diamine (TEMED) and 
ammonium persulfate (APS) during sonication to initiate radical polymerization. The resultant 
nanoparticles were purified via liquid-liquid extraction in hexane. In the final stage of the 
extraction process, bubbling nitrogen gas into the nanoparticle solution evaporated off excess 
hexane. The particles were then dialyzed in 100 kD MWCO dialysis units for several days and 
stored until use. The amount of heparin in the solution was determined by lyophilizing a small 
aliquot of the solution. Similar to the heparin-coated polystyrene particles, VEGF was incubated 
 88 
at 4˚C at 100 mg/ ml, followed by 365 nm wavelength UV light activation for 10 min to lock 
VEGF covalently to the surface. Excess VEGF was removed by dialysis in 100 kD MWCO 
dialysis units. 
 
5.2.2 Excisional skin wound model 
Seven to nine week old female db/db mice were used for these studies under the ACR 
protocol #2010-011. Mice were anesthetized with 2–3% isoflurane in an induction chamber and 
kept under anesthesia during the whole surgery. The back of the mice was shaved, washed with 
betadine and 70% ethanol and a dose of buprenorphine (2.5 mg/kg) was administered, 
subcutaneously, prior to the surgery. Four excisional wounds were made in the skin aside the 
midline of the animal using a 6-mm biopsy punch. 40 μl of Fib3+hcV (200ng), Fib3+lcV(200ng), 
Fib3+Vs(200ng) or Fib3 gel alone was applied topically on the wounds and wait for gelation for 
20 minutes. The whole backs were covered with tagerderm to allow visualization and 
measurement of the wound size. All animals were observed daily for signs of inflammation and 
pain for the first 48 hours post-surgery. Wounds were photographed at day 0 and day 7, based 
on which the percentages of wound closure were calculated.  
 
5.2.3 Histological Analyses 
All animals were sacrificed at day 7 with isoflurane overdose. Four 8-mm round pieces of 
tissue were collected from each db/db mouse containing the whole wound area and the 
surrounding tissue and skin, cut precisely in half at the midline of the wound. Half of the tissues 
were fixed in 1% Paraformaldehyde (PFA) for 16-18 hrs at 4 °C, then preserved in 70% EtOH, 
and then paraffin embedded while the corresponding halves were cyro-embedded in OCT right 
after sacrifice. Paraffin sections were cut at 5 μm and the H&E stainings were performed. HALO 
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Next Generation Imaging analysis software (Indica Labs; Corrales, NM) was then used to 
analyze the images. 
5.2.4 Immunofluorescent Staining and Analyses 
For cryo-embedded samples, 25μm thickness sample slices were cut, fixed in ice-cold 
acetone for 5 min, washed with 1XPBS for 5 min before blocked for 1 hr at room temperature in 
blocking buffer: 1XPBS + 0.05% Tween-20 + 5% normal goat serum. Sections are then washed 
in 1XPBST. Primary antibodies were prepared in blocking buffer, including rabbit anti-mouse 
Keratin 14 (Biolegend; #905301; 1:200), rat anti-mouse CD31 (BD Pharmingen; #553370; 
1:100), and rabbit anti-mouse NG2(Millipore; #AB5320; 1:200). Sections were stained with 
primary antibodies overnight, then were washed with 1XPBST twice, then re-incubated with 
blocking buffer for 10 min before secondary antibody incubation. Secondary antibodies were all 
prepared at a dilution of 1:200 in blocking buffer together with 2 µg/mL DAPI. Sections were 
then incubated in secondary antibodies for 2 hours at room temperature, and subsequently 
washed with 1X PBST and 1XPBS. Sections were mounted in Antifade Gold mounting medium. 
Imaging was performed using a Nikon C2 confocal and images were analyzed using Image J. 
 
5.2.5 Statistical Analysis 
Statistical analyses were performed using Prism (GraphPad, San Diego, CA). Data were 
analyzed using a one-way analysis of variance (ANOVA) followed by a Tukey post-hoc test. The 
results are expressed as mean ± SD.  
Single, double, triple and quadruple asterisks represent p < 0.05, p < 0.01, p < 0.001 
and p < 0.0001, respectively. A p value < 0.05 was considered statistically significant. 
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5.3 Results and discussion 
 
Figure 5.1 (a) Scheme for heparin nanoparticles and VEGF clusters synthesis. (b) Db/db mice skin 
wounds were induced at day 0. Mice were sacrificed at day 7 and wound images were taken and 
analyzed for blank fibrin gel (blk), soluble VEGF + gel(Vs), low clustered VEGF (lcV) and high clustered 
VEGF (hcV) conditions. Scale bar, 1mm.  (c) Traces of wound-bed closure during seven days in vivo for 
each treatment category. (d) Quantification of the percentage of the remained wounds at day 7 (n=3-4). ** 
indicates P < 0.01. 
It is known that vascular growth is essential for effective tissue repair and is profoundly 
attenuated in preclinical models of impaired healing such as diabetic mice. To understand how 
VEGF clustering affects diabetic wound healing outomes, an excisional skin wound model was 
used to assess angiogenesis in diabetic（db/db）mice. Two types of heparin-core VEGF 
clusters with 100-fold difference of bound-VEGF density (20mg VEGF/mg heparin and 0.2mg 
VEGF/mg heparin) were synthesized as previously described (Nih L et al, in preparation), and 
encapsulated in a hydrogel prior to administration(Figure6.1a). In order to maintain accurate 
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dosage locally on the wound beds,fibrin gel depleted of fibronectin was used as a fast-
degradable carrier for these VEGF clusters.  Fibrin matrix is known for its biocompatibility and 
safety for usage in human studies186. The gelation process is also fast, stable and easy to be 
induced through Factor XIII reaction. Full thickness excision of 6-mm circle skin wounds were 
created on the back of diabetic mice at day 0 and the wounds were covered with one local 
dosage of 40µl fibrin matrix alone (blk) or fibrin matrices containing 200ng VEGF per gel in the 
format of lowly clustered VEGF (lcV) or highly clustered VEGF (hcV) or soluble VEGF (Vs). At 
day 7, mice were sacrificed and significant increased wound closure was observed visually in 
hcV condition compared with all the other three groups. Consistently, quantification of wound 
closure also showed that hcV condition reduced wound size significantly when compared with 
blk, Vs and lcV conditions (Figure 6.1b-d). 
8-mm circular pieces of mice skin covering the whole wound area and the surrounding 
tissuewere collected using biopsy punch. The samples were then cut precisely in half at the 
midline of the wound. Halves of the wounds were fixed for paraffin embedding and the other 
halves were cryo-embedded right after sacrifice. 
As expected, the analysis of H&E stained paraffin sections showed that the fibrin matrix 
was completely resolved 7 days after injury (Figure 6.2a). Since the wound area created by the 
surgical incision was clean and uninfected in diabetic mouse, the epithelial regeneration 
predominates over fibrosis with minimal wound contraction, with a predominant migration of 
neutrophils toward the central wound area, and basal cells at the cut edge of the epidermis 
showing increased mitotic activity. In the blank treated group (blk), epithelia cells from both 
edges migrated to the center of the wound and proliferated along the dermis, but no continuous 
epithelia layer was observed. Similar morphological features were seen in the Vs-treated group, 
where neutrophilia were still predominant while the monocytes and granulation tissues extended 
into the fibrin clot and filled the wound gaps. However, no continuous regenerated epithelia 
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layer was observed. In the lcV-treated group, no granulation tissue was filled into the wound 
area except in the margins.  
 
Figure 5.2 (a) Day 7 H&E representative images for blank fibrin gel (blk), soluble VEGF + gel(Vs), low 
clustered VEGF (lcV) and high clustered VEGF (hcV) conditions. Under blk condition, predominated 
neutrophils concentrated in the edges of the wound area, basal cells at the cut edges of the epidermis 
show increased mitotic activities, no regenerated epithelium formed and granulation tissue beneath the 
fibrin clot to fill the open wound area. Under Vs condition, neutrophils are still majority of inflammation 
cells that covered the surface of epidermis gap, fibrin clot deposited in the dermis are partially replaced by 
neutrophils and monocytes, still no regenerated epithelium was yielded. Under lcV condition, wound 
space is wide open and no granulation tissue filled into the wound area except in the margin. A thin layer 
of base membrane with scattered neutrophils and monocytes continuously grows to cover the base of 
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wound area. Under hcV condition, neovascularization begins emerge, collagen fibrin begins to bridge the 
wound area with increased fibroblast. A continuous layer of regenerated epithelium is formed and covers 
the whole wound area. (b) Comparison of epithelial layer thickness at day 7 (n=3-4, one way anova). ** 
indicates P < 0.01. 
 
Figure 5.3(a) Full-scan K14 immunofluorescent representative images for blank fibrin gel (blk), soluble 
VEGF + gel(Vs), low clustered VEGF (lcV) and high clustered VEGF (hcV) conditions. Scale bar, 1mm.(b) 
Quantification of K14 staining gap distance at day 7 (n=3-4, one way anova). * indicates P < 0.05. 
Interestingly, a neovascularization was observed in the hcV-treated group, where a 
majority of neutrophilia and fibrin clot were replaced by fibroblasts, macrophages and 
granulation tissue that filled the wound space. In this group, a thin layer of epidermal re-
epithelialization covering the entirely wound surface was observed. Re-epithelization post-injury 
is an important factor for wound healing. This observation indicates that the administration of 
hcV induced the greatest number of epithelial cells migration to the wound bed and promoted 
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the wound healing process. The quantification of the epithelial layer thickness. showed that the 
hcV condition yielded the greatest value compared with the all other conditions (Figure 6.2a,b).  
Cryo-sections were stained with K14 (a keratinocyte marker) to look at the keratinocyte 
layer gap at day 7. Consistently with the previous findings, the hcV condition significantly 
shortened the wound gap compared with blank gel, Vs and lcV conditions, confirming a 
significantly faster healing process (Figure 6.3a,b).  
 
Figure 5.4 (a)Representative images for CD31 and NG2 immunofluorescent staining. Top row scale bar, 
100µm. Bottom row scale bar, 50µm. (b) Schematic for endothelial cells (CD31) and pericytes (NG2) 
interaction. (c,d) Quantification of area percentage of CD31+ and NG2+ cells in granulation tissue at day 
7 (n=3-4). **** indicates P < 0.0001. 
To further examine the granulation tissue compositions and vessel formation on the 
wound bed, staining for endothelial cells (CD31) and pericytes (NG2) were performed on cryo-
sections(Figure 6.4a,b). The granulation tissue was imaged and quantified for both markers. 
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The location of the granulation tissue was chosen at the margin of the wound bed.  Quantitative 
analysis of vascular structures by CD31/NG2 double staining showed that the fibrin alone (blk), 
soluble VEGF (Vs) and low clustered VEGF (lcV) treatments had little effect on wound 
angiogenesis at day 7. In contrast, wounds treated with hcV showed a significantly increased 
density of both CD31+ and NG2+ cells at day 7, indicating a more advanced vascular formation 
in the wound site, associating the hcv administration to an advanced healing process (Figure 
6.4c,d). 
5.4 Conclusions 
Vascular Endothelial Growth Factor (VEGF) has been utilized to promote vessel 
formation and wound healing in diabetic patients, yet no promising clinical outcomes were seen 
at safe dosage. Here we propose to use highly clustered VEGF (hcV) as a therapy for diabetic 
cutaneous wound. The application of small amount of hcV (200ng per 6-mm wound) promoted 
wound healing in db/db diabetic mice after 7 days post-surgery. The administration of hcV within 
a fibrin hydrogel directly at the wound sites showed the greatest extent of wound closure and re-
epithelization compared with the administration of low clustered VEGF (lcV), soluble VEGF (Vs) 
or a blank hydrogel (blk) that does not contain the growth factor. Highly clustered VEGF (hcV) 
also promoted the formation of a granulation tissue and the recruitment of endothelial cells and 
pericytes to the wound bed. This work shows for the first time that small dosage of VEGF of 
controlled clustering density can be utilized as a therapy for diabetic wound healing. This work 
also provides a template for the design of future growth factor-based therapies in the field of 
tissue engineering.  
In conclusion, we found that highly clustered VEGF (hcV) promoted a greater wound 
healing in diabetic mice at day 7 compared with soluble VEGF and low clustered VEGF. These 
results could be explained by the effect of hcV on the VEGF receptor 2 (VEGFR2) on 
endothelial cell surface. It is already known that different presentation of VEGF can lead to 
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different VEGFR2 pathway activation. For example, it was shown that the anchorage of VEGF 
to the extracellular matrix can convey differential signaling response to endothelial cells99. It was 
also shown that when VEGF is covalently-immobilized to surface, VEGF internalization is not 
required for VEGF Receptor-2 phosphorylation187. Specifically, in diabetic mice, cell surface 
abundance of VEGFR2 is reduced and VEGFR2 signaling pathway is ligand-independent 188. 
Our observations suggest that highly clustered VEGF promotes the activation of VEGFR2 
differently, increasing the pro-repair angiogenesis in diabetic wound with trivial dosage. This 
finding could help with future presentation design of growth factors to achieve efficient wound 
healing. 
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Chapter 6  
Ultra-large nano-patterned artificial surfaces for the study of distribution effects 
of biocues such as VEGF 
 
 
6.1 Introduction 
 
Figure 6.1 Schematic of the wafer fabrication process. 
Here, we report a method of rapidly generating subcellular nano-scaled features on large 
glass wafers that can be easily accomplished within a day in batch. In addition, the wafer 
fabrication steps (Figure 6.1) were completely automated and can be readily scaled up. The 
product nano-features can then be used for Western Blots and qPCR for both protein and 
mRNA level of studies, especially for pathway activation studies from nano-patterned surfaces.  
For common cellular response on nano-patterns, cells were always seeded on top of the 
generated surface to look at cellular responses, yet few studies have been done to really 
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understand the activation of biocue pathways, especially for covalently immobilized signals. The 
pathway activation from biocues normally happen within seconds or minutes after cellular 
contact with the biocues, thus requires precise engineering controls. Here, we combine the 
nano-pattern surface together with a cell sandwich method to look at the pathway activation 
from nano-patterned covalently-linked VEGF.  
Besides the distribution of biocues, the amount of biocues is also important to 
understand the cellular outcomes. For example, surfaces loaded with different density of RGD 
can greatly impact cell adhesion and migration. Thus, besides precise distribution control, 
precise amount control is also needed to correlates cellular response with dosage. However, 
few methods are available to control protein amounts on nano-patterns. Here, we present a 
method to precisely control the amount of covalently-immobilized VEGF and observed different 
pathway response.  
Last but not least, our method can later be combined with microprinting method to easily 
create mixtures of micro-patterns and nano-patterns to study complicated biocues. We believe 
this will be able to harness the therapeutic outcomes on implants.  
Overall, we propose an ultra-large nano-islands surface production system, which can 
produce consistent nano-patterned surfaces in batches. This system can be utilized to generate 
nano-patterned wafer with wide range of particle sizes for different type of applications. Our 
system also has precisely control over the amount of protein immobilized on gold nano-isalnds 
and thus enable the comparison of the cellular outcomes from different dosage. This system 
allows us to perform bulk biocue distribution study, both from the sandwich assay, where we 
directly sandwich cells with the nano-patterend VEGF surfaces, and direct cell seeding on nano-
patterned surfaces. Also, this method can be combined with microprinting method to generate 
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modified nano-pattern within specific micro-scale microprinting area. This method is also 
applicable to different protein immobilization. 
6.2 Materials and methods 
6.2.1Materials 
The alkanethiols (1-mercapto-11-undecyl)septa(ethylene glycol) amine (EG-NH2) and 
(1-mercapto-11-undecyl)tetra(ethylene glycol) (EG-OH) were purchased from Prochimia (Sopot, 
Poland). 5000 Da methoxy(ethylene glycol)silane (mPEG-silane) purchased from Laysan Bio 
(Arab, AL, USA). Heparin sodium salt from porcine intestinal mucosa purchased from Alfa Aesar 
(Ward Hill, MA, USA). p-azidobenzoyl hydrazide (ABH) from bioworld (Dublin, OH, USA). 
Human vascular endothelial growth factor A165 (VEGF) was obtained from Genentech. Human 
umbilical vein endothelial cells (HUVECs), endothelial cell basal and growth media (EBM-2 and 
EGM-2 respectively) were purchased from Lonza (Basel, Switzerland). Reagents used in the 
gold nanopatterned wafer fabrication were standard reagents issued in the Integrated Systems 
Nanofabrication Cleanroom facility at University of California, Los Angeles. 
Polydimethylsiloxane (PDMS) sheets were made using the Sylgard 184 silicone elastomer kit 
from Dow Corning (Midland, MI, USA) following the manufacturer’s recommendation. The 
following biological buffers were made up in-house, namely, phosphate buffered saline (PBS; 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4), PBST (PBS + 0.05% 
Tween-20), Tris buffered saline (TBS; 137 mM NaCl, 20 mM Tris, pH 7.6), TBST (TBS + 0.1% 
Tween-20), lysis buffer (150 mM NaCl, 50 mM Tris pH 7.4, 1% nonidet p-40, 0.25% sodium 
deoxycholate, 1 mM EDTA, 1 mM sodium vanadate, 10 mM b-glycerophosphate, 20 µg/mL 
aprotinin, 20 µg/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride). All other reagents and 
products were purchased from Fisher Scientific and used as supplied unless otherwise noted. 
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6.2.2 Gold nanopatterned wafer fabrication 
Nanopatterns comprising discs of diameter 0.5 µm at a pitch of 1.67 µm were generated 
via photolithography using a stepper. Processing conditions at each step were optimized and 
verified using identical wafers that had been coated with opaque chromium backing (30 nm) that 
facilitated imaging using the AMAT 7830i CD-SEM. Briefly, ultraflat fused silica wafers 
(university wafers) were primed with hexamethyldisilazane (HDMS), spin-coated with AZ® nLOF 
5510 negative tone lift-off photoresist to a film thickness of 1 µm, then baked at 91 °C in 
contact-mode for 60 s. Following, the wafers were subjected to i-line (l = 365 nm) exposure in 
the ASML 5500 optical stepper using a reticle to create holes of diameter 0.5 µm at a pitch of 
1.67 µm. The exposed wafers were baked at 110 °C in contact-mode for 60 s, and then puddle-
developed with Microposit MF-319 developer for 60 s. Any residual photoresist in the holes was 
removed by oxygen plasma ashing for 1 minute at 50 °C. 5 nm titanium and 30 nm gold was 
deposited sequentially on the wafers using an e-beam evaporator at a rate of 1 Å/s each. Lift-off 
was conducted by immersion in AZ® 300T photoresist stripper at 80 °C for 5-10 min, following 
by immersion in acetone for 2 min in a sonicating bath. Wafers were washed in a cascade rinser 
for 5 min, blow-dried, then sent for dicing using a Disco DAD321 Dicing Saw. The resulting 
diced silica pieces were washed sequentially in acetone, isopropanol and methanol, blow-dried, 
then stored under argon until use. Substrates with a continuous gold film were simply fabricated 
by e-beam evaporation of 5 nm titanium and 30 nm gold on cleaned standard laboratory glass 
slides. The gold substrates were stored under argon until use. 
 
6.2.3 Heparin-ABH synthesis 
Heparin was modified with the photoreactive group ABH as reported previously187. 
Briefly, heparin was oxidized with sodium periodate to introduce aldehyde groups that could 
then be reacted with the hydrazide group on ABH. The mixture was then dialyzed against water 
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to remove the unreacted components and salts, lyophilized, then stored at -20 °C in the dark 
until use. 
 
6.2.4 Discontinuous nano-patterned VEGF surface (cVc) processing 
Nanopatterned substrates were immersed in a 2 mM alkanethiol mixture (comprising 1 
% EG-NH2 and 99 % EG-OH) in ethanol under argon for 18-24 h. Following incubation, the 
substrates were washed twice in ethanol, blow-dried, then immersed in 1 (w/v)% mPEG-silane 
and 1 (v/v)% triethylamine in toluene under argon for 5 h. Following incubation, the substrates 
were washed sequentially in toluene, ethanol, 70% ethanol, PBS, then immersed in 1 mg/mL 
heparin-ABH in PBS, pH 9-9.5 for 2 h. Following incubation, the substrates were washed three 
times with PBST, then blocked in 1% bovine serum albumin (BSA, fraction V, heat shock 
treated) in PBS for 1 h. Following incubation, the substrate were incubated in 1 % BSA in PBS 
with (or without, for the control condition) 100 ng/mL VEGF overnight at 4 °C. Following 
incubation, the substrate was exposed to UV (l = 365 nm, 3 mW/cm2) for 10 min. The 
substrates were washed three times with PBST, then incubated with 1 mg/mL heparin in PBST 
at 4 °C until use (within 2 days).  
 
6.2.5 Homogenous VEGF surface processing (Vc) 
Homogenous gold substrates were immersed in a 2 mM alkanethiol mixture (comprising 
1 % EG-NH2 and 99 % EG-OH) in ethanol under argon for 18-24 h. Following incubation, the 
substrate were incubated in 1 % BSA in PBS with (or without, for the control condition) 100 
ng/mL or 10 ng/ml VEGF overnight at 4 °C. Following incubation, the substrate was exposed to 
UV (l = 365 nm, 3 mW/cm2) for 10 min. The substrates were washed three times with PBST, 
then incubated with 1 mg/mL heparin in PBST at 4 °C until use (within 2 days).  
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6.2.6 Bound VEGF quantification 
For quantitation of surface-bound VEGF, PDMS molds with wells of known dimensions 
were fixed over the substrate. Direct enzyme-linked immunosorbent assay (ELISA) was carried 
out using human VEGF165 biotinylated goat pAb (R&D Systems, Minneapolis, MN, USA) and 
streptavidin horseradish peroxidase.  
 
6.2.7 Bound VEGF visualization 
For imaging of VEGF on the substrates, human VEGF mouse mAb (clone 26503) (R&D 
Systems) and goat anti-mouse IgG-AlexaFluor 555 (Molecular Probes, Life Technologies, 
Grand Island, NY, USA) were used to detect the surface-bound VEGF. Slides were imaged on 
the Axio Observer Z1 (Carl Zeiss, Jena, Germany) using the EC Plan-Neofluar 100x/1.3 Oil DIC 
objective. 
 
6.2.8 Cell culture conditions 
Primary normal HUVECs were purchased from Lonza (CC-2519).  HUVECs were 
cultured in endothelial growth media (EGM-2) until 80% confluency before passaging into a 
fresh flask.  In this way, HUVECs were continually expanded in cell culture flasks and used from 
passage 4 to 6. For the experiments, HUVECs were passaged onto fibronectin-coated PDMS 
sheets as reported previously187. Briefly, PDMS sheets were incubated with 5% (3-
aminopropyl)triethoxysilane (APTES) in ethanol overnight at room temperature. The now 
hydrophilic PDMS sheets were washed and sterilized in 70% ethanol before incubation with 100 
μg/mL fibronectin in PBS at 37 °C, 5% CO2 in a tissue culture incubator. HUVECs were plated 
on the PDMS cell sheets at a density of 15 × 103 cells per cm2 and grown to about 80% 
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confluency over 2 days. Before the experiments, HUVECs were serum-starved in endothelial 
basal media (EBM-2; Lonza) for 6 hours. 
6.2.9 Cell exposure to VEGF conditions 
For cells exposure to VEGF in solution (Vs), EBM-2 was aspirated from the cell sheets 
and replaced with PBS with (or without, for the control condition) 2 ng/mL VEGF. This VEGF 
concentration was selected based on a mass transfer analysis to be equivalent to a surface 
VEGF concentration of 100 pg/cm187.  
For cells exposed to VEGF presented on a surface (Vc, cVc), before cell exposure, the 
substrates were washed three times with PBST, then three times with sterile PBS. Then, cell 
sheets were lifted from the petri dish with tweezers, quickly placed vertically and dabbed on a 
kimwipe at the edge to blot off excess media. The cell sheets were immediately placed cell-side 
in contact with the surface with (or without, for the control condition) VEGF. Incubation times (up 
to 2 h in the tissue culture incubator) were as indicated in the text. 
 
6.2.10 Western blot analysis 
Following VEGF exposure, cells were washed twice in ice-cold PBS containing 2 mM 
sodium vanadate, then lysed in lysis buffer (5 μL per cm2 surface area). The collected cell lysate 
was spun down at 13000 ×g for 10 min at 4 °C to pellet out any cell debris. The protein 
concentration of the cell lysate was evaluated using the DC protein assay kit from Bio-Rad 
(Hercules, CA, US) following the manufacturer’s protocol. 5 μg protein was loaded into each 
well of a 4-12 % gradient Tris-glycine SDS-PAGE gel (Novex or Bolt gel from Invitrogen, Life 
Technologies) run using the manufacturer’s recommended protocol. The separated proteins 
were transferred to nitrocellulose membrane via wet tank transfer using ice-cold Tris-glycine 
buffer containing 20% methanol for 350 mA for 2 hr at 4 °C. Membranes were blocked with 5% 
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milk in TBST for 1 h at room temperature before blotting with the desired primary antibodies in 
5% milk in TBST overnight at 4 °C. Primary antibodies (all purchased from Cell Signaling 
Technology (Danvers, MA, USA) unless otherwise stated) used were: phospho-VEGFR-2 
(Y1175) rabbit mAb (#2478), VEGFR-2 (55B11) rabbit mAb (#2479), phospho-p44/42 MAPK 
(T202/Y204) antibody (#9101),  p44/42 MAPK antibody (#9102), phospho-p38 MAPK 
(T180/Y182) antibody (#9211),  p38 MAPK antibody (#9212), phospho-Akt (S473) (193H12) 
rabbit mAb (#4058), Akt antibody (#9272), phospho-VEGFR-2 (Y1214) rabbit pAb (#44-1052 
from Invitrogen).  The secondary antibody was goat anti-rabbit IgG (H+L) horseradish 
peroxidase conjugate from Invitrogen (#G-21234) diluted in 5% milk in TBST. The blots were 
developed with Amersham ECL Prime Western blotting detection reagent (GE Healthcare, 
Piscataway, NJ, USA) before imaging with the Gel Doc XR+ system with Image Lab Software 
(Bio-Rad). Band intensities were quantified using Image Lab. 
 
6.2.11 Quantitative real-time PCR 
Following VEGF exposure, cells were washed once with PBS, then incubated with 
0.25% trypsin-EDTA (Gibco, Life Technologies) for 3 min at 37 °C. Trypsin was immediately 
quenched with 4% fetal bovine serum (Atlanta biologicals, Flowery Branch, GA, USA) in PBS. 
The collected cell suspension was spun down at 500 ×g for 5 min at 4 °C to pellet out the cells. 
Lysis buffer from the RNAqueous micro total RNA isolation kit (Ambion, Life Technologies) was 
immediately added to cell pellet. Total RNA was isolated from the cells following the 
manufacturer’s protocol. RNA concentration was evaluated by UV absorbance (l = 260 nm). 
Reverse transcription was carried out by loading 0.25 μg RNA per reaction of the iScript 
Advanced cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR (qPCR) was carried out 
using 10 ng cDNA per reaction of the Maxima SYBR Green/ROX qPCR master mix (Thermo 
Scientific, Pittsburgh, PA, USA) following the manufacturer’s recommended protocol for three-
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step cycling using the StepOnePlus real-time PCR system (Applied Biosystems, Life 
Technologies). Threshold cycles (CT) were evaluated by the bundled software and expression 
fold change was calculated using the delta-delta CT method assuming 100% efficiency. GAPDH 
was used as the housekeeping gene.  
 
6.2.12 Short-term exposure immunofluorescent staining 
Following VEGF exposure, cells were washed once with PBS, then incubated with 4% 
paraformaldehyde in PBS for 15 min at room temperature. The fixed cells were blocked with 
10% normal goat serum (Invitrogen) containing 0.3% Triton-X for 1 h at room temperature 
before incubating with the desired primary antibodies in 1% BSA in PBS containing 0.3% Triton-
X overnight at 4 °C. Primary antibodies used were: Jag1 (28H8) rabbit mAb (Cell Signaling 
Technologies), Dll4 (447506) rat mAb (R&D Systems), PECAM-1 (9G11) mouse mAb (R&D 
Systems). Following 3 washes with PBS, the cells were incubated with the corresponding 
secondary antibodies and Hoescht 33528 for 1 h at room temperature. Secondary antibodies 
(all from Molecular Probes, Life Technologies) used were: goat anti-rabbit IgG-AlexaFluor 488, 
goat anti-rat IgG-AlexaFluor 568, goat anti-mouse IgG-AlexaFluor 555. Following 3 washes with 
PBS, cells were coated lightly with glycerol and mounted on glass slides. Slides were imaged on 
the LSM 780 confocal laser scanning microscope (Carl Zeiss) using the EC Plan-Neofluar 
40x/1.3 Oil DIC objective. For ease of imaging, a scratch was created using a yellow pipette tip 
on the cell sheets prior to VEGF exposure and cells on the edges of the scratch were imaged. 
 
6.2.13 Overnight HUVEC spreading on cVc surface 
Before cell exposure, the cVc surfaces were washed three times with PBST, then three 
times with sterile PBS. HUVEC cells were then seeded at a density of 33,333 cells per ml in 
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EGM-2 depleted of VEGF and Fibronectin. After 21 hours, cells were fixed with ice-cold 
methanol for 15 min. The cell samples were then washed 3 time with PBS. The fixed cells were 
blocked with 10% normal goat serum (Invitrogen) containing 1% BSA, 0.3M Glycine and 0.1% 
Tween-20 for 1 h at room temperature before incubating with Paxillin (5H11) mouse mAb (EMD 
Millipore) in the same blocking buffer overnight at 4°C. Following 3 washes with PBS, the cells 
were incubated with goat anti-rabbit IgG-AlexaFluor 555(Life Technologies) and DAPI for 1 h at 
room temperature. Following 3 washes with PBS, cells were coated lightly with glycerol and 
mounted on glass slides. Slides were imaged on the LSM 780 confocal laser scanning 
microscope (Carl Zeiss). 
 
6.2.14 Microprinting on nano-patterned surface 
Nano-patterned glass surfaces were washed with acetone and ethanol, dried, then 
immersed in 1 (w/v)% mPEG-silane and 5 (v/v)% triethylamine in toluene under argon at 60°C 
for 3 days. Following mPEG-silane incubation, the substrates were washed sequentially in 
toluene and ethanol. Microprinting PDMS stamps were incubated in 0.17 (v/v)% EG-NH2 in 
ethanol for 10 min, then the stamp was put into vacuum for 20 min. Stamps were then put in 
contact with the nano-patterned glass surfaces for 20 s. Then, the substrates were incubated at 
room temperature for 1 hour. After an hour, the glass surfaces were washed with ethanol. Then, 
the slides were immersed in 0.075 (v/v)% EG-OH in ethanol under argon at room temperature 
overnight. Next day, the substrates were washed sequentially in ethanol and PBS, and dried. 
The surfaces were then reacted with fibronectin in 10 mM MES (pH 6) at room temperature for 1 
hour. The concentration of fibronectin used was 1 mg/mL; and, the molar ratio of NHS and EDC 
used was 20,000:115,000:1 (NHS:EDC:Fibronectin). Then, the slides were washed with PBS. 
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6.2.15 Cell seeding on microprinted fibronectin-immobilized nano-patterned surface 
D1 cells in DMEM were seeded on the nano-patterned surfaces for 20 min at density of 
100,000 cells/mL. Then, additional DMEM with 5 (v/v)% FBS and 1 (v/v)% penicillin-
streptomycin was added to provide sufficient cell attachment to the surfaces. The slides with 
cells were then incubated for 16-18 hours. Next day, the slides with cells attached were 
incubated with 1% paraformaldehyde in PBS at room temperature for 15 min. Then, the slides 
were washed with PBS. The fixed cells were then blocked with 10% normal goat serum 
(Invitrogen) containing 1 (w/v)% BSA, 0.1% Tween-20, and 0.3 M glycine at room temperature 
for 1 hour before incubating with the desired primary antibodies (in the same blocking buffer) at 
4°C overnight. The primary antibodies used were: Paxillin and rabbit anti-fibronectin. After the 
primary antibody incubation, the cells were washed sequentially with PBS containing 0.05% 
Tween-20 and PBS. The cells were then incubated with the corresponding secondary 
antibodies and DAPI at room temperature for 2 hours. The secondary antibodies used were: 
goat anti-mouse IgG-AlexaFluor 647, goat anti-rabbit IgG-AlexaFluor 488, and rhodamine-
phalloidin. Then, the cells were again washed with PBS containing 0.05% Tween-20 and PBS 
sequentially. The nano-patterned surfaces with cells were then mounted on glass slides with 
antifade mountant. The slides were then imaged on Nikon C2. 
 
6.2.16 Statistical analysis 
All experiments were conducted in at least triplicates with the results reported as mean ± 
standard error mean. One-way ANOVA with a Tukey post-test was used to establish statistical 
significance (p < 0.05) if shown.  
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6.3 Results and discussion 
6.3.1 Gold nanopatterned wafer fabrication 
The ASML stepper in conjunction with standard lithography techniques was chosen for 
the rapid fabrication of large areas (4- to 6-inch wafers) with sub-micron (hundreds of nm) 
features (Figure 6.1). Fused silica or glass was chosen as the substrate for ease of imaging in 
later experiments. In order to generate well-resolved features on the glass substrate, a negative 
photoresist was chosen in conjunction with lift-off to leave standing cylinders of titanium/gold on 
an ultra-flat glass surface.  
The reticle used in the stepper to generate holes in the photoresist was initially designed 
to leave 0.3 µm holes at a pitch of 1.67 µm. Optimization of both the exposure energy and the 
focus offset using a die matrix typically generates a series of holes ranging from 0.4 to 0.8 µm 
(Figure 6.2A). As expected, higher exposure energies (towards the right of the matrix in Figure 
6.2A) resulted in smaller features. However, over-exposure of the AZ® nLOF 5510 negative 
photoresist resulted in problems during lift-off and the absence of any nanopattern at worst. The 
final exposure parameters used for the substrates used in this paper were thus chosen to 
generate 0.7 µm holes at a pitch of 1.67 µm (Figure 6.2B, left). Following metal deposition and 
photoresist lift-off, the features generated were 0.7 µm islands at a pitch of 1.67 µm (Figure 
6.2B, right). Representative images of ultra-flat glass wafer and nano-patterned glass wafer 
were shown in Figure 6.2C. After patterning, each glass wafer can be sliced into three 2.2cm by 
6.7cm glass slide. This gives ultra-large nano-patterned area of 14.74 cm2 per slide. Each batch 
production can produce 10 nano-patterned wafers which eventually yielded 30 ultra-large nano-
patterned glass slides. It is observed that glass surface showed a golden yellow color after 
nano-patterning, yet still transparent (Figure 6.2C).  
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Figure 6.2 CD-SEM images of photoresist mask and gold nanopatterned glass wafers. (A) Representative 
matrix of focus offset (vertical axis) and UV exposure energy (horizontal axis) used to generate a range of 
hole sizes and morphologies on the photoresist layer using a photomask designed for 300 nm holes at a 
1.67 μm pitch. Numbers on the panels reflect the approximate hole diameters measured using the 
imaging software. (B) Size and morphology of the features before and after gold deposition using an e-
beam evaporator. The photoresist mask (left) was lifted off using AZ300T stripper, followed by sonication 
in acetone to reveal standing gold cylinders (right).(C) Representative photo of nano-patterned substrate. 
6.3.2 VEGF conjugation to nano-patterned glass surface 
In our study, we utilize VEGF as a template. Vascular endothelial growth factor A 
(VEGF) is a key protein involved at multiple stages of blood vessel formation during 
development and also in the adult as physiologic and pathologic angiogenesis189. Current 
therapeutic strategies involving VEGF aim to disrupt the interaction of VEGF and its key 
receptor, VEGF receptor-2, (VEGFR-2) thereby blocking the angiogenic response in tumors. In 
contrast, pro-angiogenic strategies that attempt to promote angiogenesis using VEGF (with bulk 
dosage or gene transfection) in areas of tissue ischemia have been less successful, suggesting 
the existence of a gap in our knowledge of how VEGF functions to promote physiologically 
normal angiogenesis. 
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At the cellular level, VEGF-VEGFR signaling has been shown to trigger different 
intracellular signaling cascades associated with cell survival, proliferation and migration97. 
During angiogenesis, the activation of these cascades must somehow be weighted in order to 
effectuate the distinct phases of angiogenesis. Thus, the facile application of soluble VEGF, 
often used to maintain and expand endothelial cells in vitro, is unlikely to translate into an 
effective therapeutic strategy for promoting the formation of a complex and mature vascular 
network. Indeed, many well-known in vitro models of sprouting angiogenesis require the 
assistance of fibroblasts for the formation of stable vessels, even in the constant presence of 
VEGF190, 191. This suggests that the homogenous application of soluble VEGF is necessary but 
not sufficient for inducing stable vessel formation. In fact, other presentations of VEGF have 
shown to efficiently induce healthy vessel formation, such as covalently-linked VEGF and 
clustered VEGF. However, the distribution of VEGF has not been fully investigated. Here, we 
hypothesis that besides the presentation of VEGF (soluble, electrostatically or covalently-bound 
VEGF), the nano-scale distribution of VEGF also regulates VEGFR-2 pathway and affect 
cellular outcomes.  
This work builds on that foundation by demonstrating that the endothelial cell response 
can be further tuned by a discontinuous distribution of covalently-bound VEGF. Here, we 
describe a method for rapidly fabricating large areas of nanoscaled gold islands that can be 
chemically conjugated to VEGF via heparin. Endothelial response to nano-scaled subcellular 
discrete distribution of VEGF was found to differ from that of a continuous surface of VEGF. 
This posits the patterning of VEGF as an alternative means of directing endothelial cell 
response in a spatiotemporal manner.VEGF was immobilized on the homogeneous gold 
surfaces (Vc) and gold nanopatterned (cVc) surfaces following the bind-and-lock strategy 
previously published by our lab (Figure 6.3)192. The primary advantage of this technique is the 
presentation of VEGF in a physiologically relevant context (bound to heparin) that enhances 
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signal transduction193. Heparin binding also improves the stability of VEGF and increases its 
half-life from 100 min to 2 days at 37 °C187. Briefly, a 1% amine-functionalized self-assembled 
monolayer (SAM) of alkanethiol was formed on the gold. The exposed glass was then 
passivated with a layer of mPEG-silane to minimize surface fouling during subsequent 
conjugation steps194. Later, oxidized heparin functionalized with the UV-crosslinkable ABH 
group was conjugated to the amine-functionalized SAM via reductive amination. Thus, VEGF 
was allowed to “bind” to the immobilized heparin via affinity interaction. In the end, the bound 
VEGF was “locked” to the heparin backbone via UV crosslinking.  
 
Figure 6.3 Schematic of the VEGF conjugation procedure. 
Due to the large spacing between the gold islands, the gold surface coverage on the 
nanopatterned glass surfaces amounted to less than 10% of the total surface area. Without 
passivation of the glass background via mPEG-silane, the amount of non-specifically bound 
VEGF overwhelmed the amount of specifically bound VEGF (Figure 6.4A). When comparing 
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immobilized VEGF amount on homogeneous gold surface (Vc) with and without silanization, this 
additional processing step did not significantly impact the VEGF conjugation process. After 
silanization, the bulk VEGF surface concentration of cVc condition (204 ± 94 pg/cm2) was 
approximately 5 times lower than Vc (546 ± 22 pg/cm2) under the same processing conditions 
(same amount of VEGF dosage). In later experiments, gold surfaces were generated with this 
surface concentration of VEGF (denoted Vc high) and also a lower surface concentration of 
VEGF (denoted Vc low) to match the bulk VEGF concentration on cVc. 
 
Figure 6.4 Specific binding of VEGF to gold nanopatterned features on glass. (A) Bulk surface 
concentration of VEGF on homogeneous gold-coated glass (Vc), heterogeneous gold nanopatterned 
glass (cVc) and bare glass (Vg) following identical VEGF conjugation protocols. Silanization of exposed 
glass surfaces using mPEG-silane was necessary to reduce non-specific adsorption of VEGF to the non-
patterned surface (compare clear and filled columns). (B) Conjugated VEGF on gold nanopatterned glass 
visualized by standard immunofluorescent techniques employing a primary anti-VEGF antibody and 
fluorescently-tagged secondary antibody. The gold islands were visualized under brightfield and overlaid 
with the fluorescent images, demonstrating specific binding of VEGF to the gold nanofeatures (cVc+). The 
no VEGF control (cVc-) processed in the absence of VEGF demonstrated no fluorescence under identical 
imaging conditions. (C) Representative immunofluorescent images of HUVECs seeding on cVc surface. 
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VEGF binding to the gold nanopatterns was then verified by sequential incubation of the 
surface with a VEGF antibody and an AlexaFluor 555-labeled secondary antibody. Gold 
nanopatterned surfaces conjugated to VEGF displayed a fluorescent nanopattern corresponding 
with the gold nanopattern imaged via brightfield microscopy (Figure 6.4B). Control surfaces 
processed identically but without VEGF incubation did not display the fluorescent nanopattern 
under identical imaging parameters. The seeding of HUVEC cells on the cVc surface also 
showed clear paxillin signal co-localized with gold nano-patterns, indicating that nano-patterned 
surface of VEGF with heparin can also be used as a biocue to promote cell attachment (Figure 
4C).  
 
6.3.3 Protein level analysis on VEGFR-2 phosphorylation time course 
To study the effect of nano-scaled distribution of immobilized VEGF on endothelial cell 
VEGFR-2 activation, a sandwich assay was utilized as previously published187.  Briefly, cells 
cultivated on fibronectin-coated PDMS sheet was first sandwiched together with cVc and Vc 
surfaces for 5, 10, 15, 30, 60 and 120 min respectively, then collected for Western Blot analysis. 
Soluble VEGF (Vs, 2ng/ml) was also performed as a control group. Benefited from ultra-surface 
area of this nano-patterned surface, enough lysate was collected easily for the standard 
Western Blot analysis.  
The binding of VEGF to VEGFR-2 induces receptor dimerization and 
autophosphorylation of specific intracellular tyrosine residues. In particular, Y1175 and Y1214 
are major phosphorylation sites associated with the activation of the MAPK pathways in 
endothelial cells, activating intracellular signaling cascades critical for proliferation, migration 
and survival97, 98. 
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In the soluble VEGF control group, the administration of soluble VEGF (Vs+) results in a 
large spike in relative VEGFR-2 phosphorylation at Y1175 (pY1175/VEGFR-2) within minutes 
as expected (Figure 6.5A). Background levels of pY1175/VEGFR-2 in the absence of VEGF 
(Vs-) were close to zero at all timepoints. Similarly, Y1214 phosphorylation (pY1214/VEGFR-2) 
also increases, but tails off more gradually with time (Figure 6.5B). The background levels of 
pY1214/VEGFR-2 in the absence of VEGF (Vs-) is likely due to the culture conditions of the 
HUVECs on fibronectin-coated PDMS. Such background levels were not observed in HUVECs 
cultured on tissue-culture plastic (unpublished data), suggesting that the presence of integrin 
ligand such as fibronectin or changes in mechanical stiffness of the culture substrate have 
effects on VEGFR-2 phosphorylation at Y1214.  
 
Figure 6.5 Time course for the phosphorylation status of VEGFR-2 at the tyrosine 1175 and 1214 residue 
(pY1175, pY1214 respectively) of cells in contact with different forms of VEGF quantified using Western 
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blot densitometry. (A, B) Phosphorylation time course of VEGFR-2 from cells in contact with soluble 
VEGF (Vs+; solid circles) or the no VEGF buffer control (Vs-; empty circles). (C, D) Phosphorylation time 
course of VEGFR-2 from cells in contact with VEGF covalently conjugated on a continuous gold film at 
high concentration (Vc+ high; solid squares) or low concentration (Vc+ low; solid circles), and gold film 
with no VEGF (Vc-; empty circles). (E, F) Phosphorylation time course of VEGFR-2 from cells in contact 
with VEGF covalently conjugated on a gold nanopattern (cVc+; solid circles), and gold nanopattern with 
no VEGF(cVc-; empty circles). (G) Relative phosphorylation of ERK1/2. (H) Relative phosphorylation of 
p38. (I) Relative phosphorylation of Akt. 
In the presence of covalently-bound VEGF, only the condition with high amount of VEGF 
immobilized (Vc+ high) showed sustained Y1175 phosphorylation levels while low amount of 
VEGF immobilized gold surface (Vc+ low) and directly exposure to continuous gold surface 
without VEGF (Vc-) conditions showed Y1175 phosphorylation level close to zero at all time 
points (Figure 6.5C). Thus, with homogeneous immobilization of VEGF, high amount of VEGF 
(546 ± 22 pg/cm2) was needed in order to activate Y1175 phosphorylation. Y1214 
phosphorylation of Vc+ high condition remained comparable to that in the presence of soluble 
VEGF at early time points (Figure 6.5D). Little Y1214 phosphorylation was observed in Vc+ low 
condition, consistent with the trend observed for Y1175 phosphorylation. Consistent with the Vs- 
control, the background levels of pY1214/VEGFR-2 on Vc- remained slightly elevated due to the 
effects of Fibronectin-coated PDMS sheets. 
In contrast, nanopatterned covalently-bound VEGF (cVc+), which has same amount of 
VEGF as Vc+ low condition, resulted in similar levels of Y1175 phosphorylation as Vc+ high 
condition (Figure 6.5E). Background levels of pY1175/VEGFR-2 on the respective control, cVc- 
(exposure to a nanopatterned gold without VEGF), were close to zero. This indicates that the 
discontinuous distribution of covalently-bound VEGF (cVc+) is more efficient than homogeneous 
immobilization of VEGF (Vc+). No difference of pY1214/VEGFR-2 was seen between cVc+ and 
cVc- condition, indicating the pY1214 requires higher dosage of cVc to be activated (Figure 
6.5F).  
Overall, the most interesting finding in Y1175 and Y1214 phosphorylation study is that 
lowering the surface VEGF concentration to match the bulk cVc VEGF concentration (Vc+ low) 
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did not result in significant phosphorylation of Y1175 as observed in cVc condition (Figure 
6.5C), suggesting that the nanopatterned discontinuous distribution of equivalent masses of 
VEGF is more efficient at Y1175 phosphorylation in VEGFR-2 activation pathway.  
For simplicity, future experiments will focus on a comparative study of the different 
VEGF presentations, henceforth referred to as Vs for soluble VEGF, Vc for covalently-bound 
VEGF, and cVc for clustered (nanopatterned) covalently-bound VEGF. 
The phosphorylation of VEGFR-2 at specific residues leads to the activation of 
downstream signaling cascades resulting in different cellular outcomes97, 98. For example, 
activation of the ERK1/2 MAPK pathway following Y1175 phosphorylation is typically associated 
with the proliferative response in HUVECs. While activation of the p38 MAPK pathway following 
Y1214 phosphorylation is associated with the migratory response in HUVECs. Activation of the 
anti-apoptotic Akt pathway is also associated with multiple aspects of vascular homeostasis and 
angiogenesis195. 
In response to the addition of soluble VEGF, the phosphorylation of these protein 
kinases typically peaks within 30 min196-198. Thus, the relative phosphorylation of these kinases 
would have decreased by the 120-min timepoint, either due to consumption of VEGF, or 
internalization and degradation of VEGFR-2. Interestingly, nanopatterned VEGF (cVc) showed 
the opposite trend with initially low levels of ERK1/2 and p38 phosphorylation (at 30 min) that 
increased over time (at 120 min; Figure 6.5G,H). Overall, it also appeared that covalently-bound 
VEGF, in all forms (Vc and cVc) was more effective at triggering the p38 and Akt pathways 
(Figure 6.5H,I). The extended p38 phosphorylation kinetics is congruent with the results 
reported by Chen and colleagues using collagen-bound VEGF although they did not report data 
past the 30-minute timepoint99. Chen and colleagues also reported reduced levels of Akt 
phosphorylation in their experiment setup when comparing collagen-bound VEGF with soluble 
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VEGF. However, with our set up, we observe a slight, though not statistically significant, 
increase in Akt phosphorylation, suggesting that the presentation of heparin-bound VEGF in our 
experimental setup may be more favorable for promoting vasculogenesis and/or angiogenesis. 
Overall, it is proven that this ultra-large nano-patterned surface can be utilized to 
effectively test the protein level of biocue activations. 
 
6.3.4 Changes in gene expression in response to nanopatterned VEGF 
The initial stages of angiogenic sprouting involve the activation of the quiescent 
endothelium, selection of the leading tip cell and consequent lateral inhibition of the neighboring 
cells, which become stalk cells54, 199. The differentiation of the endothelial cells into tip and stalk 
cells is marked by an increase in Notch signaling via the expression of Notch ligands, Dll4 and 
Jag1200. Also, during angiogenesis process, Notch signaling has been show to result in the 
differential regulation of VEFGR-1, 2, 3201, 202. Thus, we proceed with the qPCR analysis for 
these specific genes. 
At the 30 min timepoint, there was no significant fold change in VEGFR mRNA levels 
(Figure 6.6A, B, C). By the 120 min timepoint, Vs resulted in a statistically significant 
upregulation of VEGFR-1 and VEGFR-2, but not VEGFR-3 gene expression.  Notably, there 
were no statistically significant changes to the mRNA levels of all three VEGFRs in the 
presence of cVc. Interestingly, cVc surface showed an increased trend in VEGFR-2 expression 
compred with Vc low, further confirming the effects of the discontinuous distribution.  
The Notch receptor-ligand pathway forms a close counterpart to the VEGF receptor-
ligand pathway in directing endothelial cell response during sprouting angiogenesis200. In 
particular, the Notch ligands Dll4 and Jagged1 are known to form an antagonistic pair in 
regulating tip and stalk cell phenotype, with Dll4 predominantly expressed in tip cells, and 
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Jagged1 and Dll1 in the adjacent stalk cells140, 203, 204. Statistically, there were no significant 
changes to the mRNA levels of all three Notch ligands under the different incubation conditions 
(Figure 6.6 D, E, F), although Dll4 appeared to be slightly upregulated in the presence of Vs. 
This could suggest that 120 min is not sufficiently long for the establishment of Notch signaling 
and differential expression of the different Notch ligands. On the other hand, roughly even 
populations of stalk and tip cells may have been induced by the treatment, averaging out to a 
basal level of Notch ligands following bulk harvest of the endothelial cells. 
 
Figure 6.6 Fold change in mRNA levels (relative to the corresponding negative controls) of the VEGFRs 
and Notch ligands from cells in contact with different forms of VEGF quantified using quantitative real time 
PCR. (A) Fold change in VEGFR-1 mRNA levels. (B) Fold change in VEGFR-2 mRNA levels. (C) Fold 
change in VEGFR-3 mRNA levels. (D) Fold change in Dll4 mRNA levels. (E) Fold change in Jag1 mRNA 
levels. (F) Fold change in Dll1 mRNA levels. 
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6.3.5 2D cellular response to nanopatterned VEGF 
Due to the differential expression of Notch ligands in tip and stalk cells, we theorized that 
the lack of significant changes to the Notch ligand mRNA levels may be due to an averaging 
effect when cells were pooled for RNA extraction. We therefore proceeded to look at the 
intracellular distribution of these ligands at the point of cell harvest – 30 min and 120 min (Figure 
6.7). Surprisingly, we found changes in the intracellular distribution in the Notch ligands as early 
as 30 minutes into the incubation with VEGF. This timepoint is typically too short for there to be 
changes in protein expression due to changes in gene expression in response to external 
stimuli. Notably, with soluble VEGF treatment, Dll4 was expressed as punctate structures in the 
cytoplasm at both timepoints (Figure 6.7B, E). These structures were less prominent in cells 
exposed to VEGF in other configurations.  
 
Figure 6.7 Intracellular distribution of Jagged1 (green) and Dll4 (red) in cells in contact with different forms 
of VEGF imaged using confocal microscopy. Hoescht 33528 (blue) was used to stain the nuclei. (A-C) 
Intracellular distribution of Jagged1, Dll4, and the overlay (with Hoescht) in cells exposed to Vs for 30 
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min. (D-F) Intracellular distribution of Jagged1, Dll4, and the overlay (with Hoescht) in cells exposed to Vs 
for 120 min. (G-I) Intracellular distribution of Jagged1, Dll4, and the overlay (with Hoescht) in cells 
exposed to Vc high for 30 min. (J-L) Intracellular distribution of Jagged1, Dll4, and the overlay (with 
Hoescht) in cells exposed to Vc high for 120 min. (M-O) Intracellular distribution of Jagged1, Dll4, and the 
overlay (with Hoescht) in cells exposed to Vc low for 30 min. (P-R) Intracellular distribution of Jagged1, 
Dll4, and the overlay (with Hoescht) in cells exposed to Vc low for 120 min. (S-U) Intracellular distribution 
of Jagged1, Dll4, and the overlay (with Hoescht) in cells exposed to cVc for 30 min. (V-X) Intracellular 
distribution of Jagged1, Dll4, and the overlay (with Hoescht) in cells exposed to cVc for 120 min. 
Also at the 30 min timepoint, there appeared to be pronounced cytoplasmic localization 
of Jagged1 in cells exposed to cVc (Figure 8S), compared to the other conditions. However, this 
disappeared by the 120 min timepoint, indicative of the presence of some kind of feedback 
mechanism controlling the intracellular distribution of Jagged1. Such cytoplasmic localization of 
Jagged1 was also observed in cells incubated on Vc high for 120 min, but not for Vc low(Figure 
6.7J, P). This suggests that different VEGF amount and distribution may exhibit qualitatively 
different effects at very different timepoints, and that we may be missing out on important 
differences by limiting ourselves to short, predetermined timepoints. 
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Figure 6.8 (A)Representative of microprinting outcomes on nanopatterned surface. (B) 10X images of D1 
cells attachment on nanopatterned fibronectin surface with microprinting patterns. (C)Enlarged image of 
D1 cells seeding on nanopatterned fibronectin surface within circular microprinting patterns. 
 
6.3.6 Microprinting on nanopatterned fibronectin surfaces 
Microprinting can also be performed on this ultra-large nano-patterned surface. It can 
help to create micro-pattern on top of nano-patterning, which enables distribution study of 
biocues within an area with controlled size and shape. For example, MSCs can differentiate 
based on the shape of the micro-pattern205, but little is known about how distribution signal 
within the patterns affect cellular outcomes.   
In our study, microprinting patterns were printed on top of nano-patterned surface using 
amine-end alkanethiol, followed by biocue immobilization, such as fibronectin. This results 
fibronectin signals only on gold nano-pattern within specific micro-scale region (Figure 6.8A). D1 
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cells were then seeded on the fibronectin-immobilized surface for 20 min to allow quick 
attachment. It was observed the cells attached to the microprinting region of fibronectin (Figure 
6.8B). Clear focal adhesion can also be observed specifically on nano-patterns where 
fibronectin was immobilized (Figure 6.8C).  
 
6.4 Conclusions 
The discontinuous nano-pattern artificial surface created in this study coupled nano-
scale gold pattern with micron-scale spacing, mimicking the naturally heterogeneous distribution 
of growth factors in the naturally occurring pericellular matrix. In this study, we have shown that 
the presentation of VEGF in different forms (Vs, Vc, and cVc), triggers distinct endothelial cell 
responses. Benefiting from the ultra-large nano-pattern surface and the ease of heparin 
“locking” technique, similar type of study can be easily performed on the other growth factors 
using the same system. This nano-patterned surface can also be combined with microprinting 
technology to look at cellular response within a confined shape.  
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Chapter 7  
Conclusions and future directions 
 
 
7.1  Introduction 
The objective of this research was to study and engineer the signals that promote 
angiogenesis in wound healing process.  These signals include but not limited to growth factors 
and integrin ligands. ECM molecules such as Fibronectin, growth factors such as VEGF 
(Vascular Endothelial Growth Factors) and their receptors have been shown to be key 
regulators of angiogenesis and neovascularization, with embryos lacking these genes, resulting 
in lethality due to defects in angiogenesis1, 2. The following sections reall the proposed specific 
aim and hypotheses, describing both the major conclusions and the future directions.  
 
7.2 Specific Aim 1 (Chapter 3) 
 
This aim developed a portable imager which detects nanocapsule degradation real-time. 
The VEGF nanocapules with different protease-degradability were utilized as template in this 
study. Samples treated with protease at different time points were tested. Samples were also 
real-time imaged to monitor real-time degradation.  
Hypothesis 1: Nano-lens based computational microscopy can be utilized as an effective 
tool to monitor nanocapsule degradation, such as protein-core VEGF nanocapsules. 
By using our computation holographic microscopy based method, a lot of obstacles are 
overcome. In general, design and synthesis of biodegradable nanoparticles, without the cargo, 
require a direct method for observing and quantification of the changes in their matrix. Several 
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techniques such as Raman spectroscopy19, fluorescence resonance energy transfer20, optical 
absorption21,22,23 and Magnetic Resonance Imaging (MRI)24 have been previously utilized to 
monitor the degradation process of the nanoparticle matrix. However, these methods can only 
be used for specific types of nanoparticles and are not universally applicable for any type of 
particle. Some of the more general strategies that have been used for monitoring nanoparticle 
degradation involve measurement of weight or size by using chromatography25, dynamic light 
scattering (DLS)14 and electron microscopy (EM)26. These methods can provide an estimation of 
the nanoparticle degradation process but each has its own set of drawbacks. For example, EM 
is performed on dry samples and thus it is not possible to perform degradability measurements 
with most polymeric nanoparticles, such as hydrogels, liposomes etc. DLS, on the other hand, 
can perform measurements in solution but is not very accurate and also is quite limited in terms 
of the dynamic range of particle size and density that can be measured, often requiring large 
amounts of sample volume for each measurement.      
Here, two different testing methods were used to monitor and quantify the degradation of 
VEGF nanoparticles. The first method involves sizing the nanoparticles by discretely sampling 
the synthesis solution at different time points after addition of proteases. A second method using 
a sandwich assay was developed to monitor the live degradation process in a continuous 
manner by placing a trypsin coated coverslip on the nanoparticle/nanolens complex, also 
imaged by our computational holographic microscope. These computational imaging 
experiments were performed on both degradable and non-degradable nanoparticles, showing a 
drastic change to the polymer matrix bound together by degradable crosslinkers compared to 
the nondegradable ones. Overall, this computational holographic imaging based nanoparticle 
monitoring platform provides a much needed, cost effective and high-throughput method to 
quantify the degradation process of any type of nanoparticle using very small amounts of 
sample volume.  
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There are also some draw-backs of this technology. For examples, some size-range of 
nanoparticles may fall off the testing cover slip, rendering a biased data set.  Future 
systematically optimization of both software and sample loading coverslips will need to be done 
to enable this technology to be commercially used.  
 
7.3 Specific Aim 2 (Chapter 4) 
This aim investigated the effects of specific integrin activation on angiogenesis. A 3D 
fibin gel sprouting assay was carried out to study HUVEC sprouting and branching in vitro. Then 
a modified matrigel assay was performed on mouse model to look at neo-vessel infiltration and 
neo-vessel morphology. Later, an ischemic stroke mouse model was also utilized to study the 
neo-vessel generation and infiltration in the stroked area in vivo.  
Hypothesis 2: Integrin-specificity matrix can be utilized to as a morphogenic cue in 
guiding endothelial cell responses both in vitro and in vivo. Specific integrin activation could 
induce the generation of healthy and non-leaky vessels.  
In Chapter 4, it is shown that through engineering hydrogel materials to promote 
α3/α5β1 integrin binding with VEGF presence, a space filling and mature vasculature can be 
formed compared to hydrogel materials that promote a αvβ3 integrin binding (e.g. RGD). In vitro, 
α3/α5β1 scaffolds promoted endothelial cells to sprout and branch, forming organized extensive 
networks that eventually reached and anastomosed with neighboring branches. In vivo, α3/α5β1 
scaffolds delivering vascular VEGF promoted non-tortuous blood vessel infiltration and non-
leaky blood vessels by 10 days post stroke. In contrast, materials that promote αvβ3 integrin 
binding promoted endothelial sprout clumping in vitro and leaky vessels in vivo. This work 
shows for the first time that precisely controlled integrin activation from a biomaterial can be 
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harnessed to direct therapeutic vessel regeneration and reduce VEGF induced vascular 
permeability in vivo. 
Here, the effects on integrin specificity is only studied for angiogenesis. Future studies 
should involve other therapeutic related research directions, such as lymphagenesis. Also, the 
integrin-specificity can be tuned in all kinds of biomaterials, such as FDA-approved PEG to look 
at therapeutic outcomes on different wounds. Besides the integrin specificity, the combination of 
different integrin specificity can also be studied. It has been shown that differentintegrins are 
activatedduring different stages of angiogenesis. By using combinations of integrin-specific 
materials, optimum wound healing outcome may be achieved.   
 
7.4 Specific Aim 3 (Chapter 5) 
This aim utilized the cluster format of VEGF to treat diabetic mouse cutaneous wounds. 
The wound closure percentage, epithelial layer thickness, endothelial cell and pericyte 
infiltration percentage were all studied.  
Hypothesis 3: Clustered VEGF can promote diabetic cutaneous wound healing.  
In Chapter 5, it was found that highly clustered VEGF (hcV) promoted a greater wound 
healing in diabetic mice at day 7 compared with soluble VEGF and low clustered VEGF. These 
results could be explained by the effect of hcV on the VEGF receptor 2 (VEGFR2) activation on 
endothelial cell surface. It is already known that different presentation of VEGF can lead to 
different VEGFR2 pathway activation. For example, it was shown that the anchorage of VEGF 
to the extracellular matrix can convey differential signaling response to endothelial cells99. It was 
also shown that when VEGF is covalently-immobilized to surface, VEGF internalization is not 
required for VEGF Receptor-2 phosphorylation187. Specifically, in diabetic mice, cell surface 
abundance of VEGFR2 is reduced and VEGFR2 signaling pathway is ligand-independent 188. 
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Our observations suggest that highly clustered VEGF promotes the activation of VEGFR2 
differently, increasing the pro-repair angiogenesis in diabetic wound with trivial dosage. This 
finding could help with future presentation design of growth factors to achieve efficient wound 
healing. 
For this specific study, only two different types of VEGF clusters were utilized. It is still 
not clear on that mechanism regarding how different VEGF clusters function. It was shown by 
previous lab member that the size of VEGF clusters doesn’t vary yet the loading amount of 
VEGF can be controlled to have order of magnitude difference. It is possible that the effects of 
hcV merely comes from the exposed amount of VEGF within certain area. It is also possible that 
the orientation and attachment angle of VEGF also plays a role.  
 
7.5 Specific Aim 4 (Chapter 6) 
This aim designed a large nano-patterned surface to study the distribution effects of 
VEGF. VEGF was immobilized to nano-islands on ultra-flat glass surface which is about 600-
700nm in diameter.  Homogenous immobilized VEGF was used as control. VEGFR-2 activation 
study was performed using Western Blots and qPCR. HUVECs were later directly seeded on 
the nano-patterned surface to look at cell attachment and spreading. 
Hypothesis 4: The discontinuous distribution of VEGF immobilization on nano-patterned 
surfaces will result in a distinct VR-2 phosphorylation pattern, downstream signal, EC 
morphology and phenotype compared with homogenous immobilized VEGF. Both western blot 
analysis and PCR technique can be used to analyze the outcomes on the protein and mRNA 
expression levels.  
The discontinuous nano-pattern artificial surface created in Chapter 6 coupled nano-
scale gold pattern with micron-scale spacing, mimicking the naturally heterogeneous distribution 
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of growth factors in the naturally occurring pericellular matrix. In this study, we have shown that 
the presentation of VEGF in different forms (Vs, Vc, and cVc), triggers distinct endothelial cell 
responses. Benefiting from the ultra-large nano-pattern surface and the ease of heparin 
“locking” technique, similar type of study can be easily performed on the other growth factors 
using the same system. This nano-patterned surface can also be combined with microprinting 
technology to look at cellular response within a confined shape.  
As a demonstration, this study only showed one type of heterogeneous VEGF 
distribution. However, there are many more we can do. We can fix the distance between gold 
islands and vary the gold island size, or we can fix the gold island size but change the distance 
between them. Instead of looking at the difference between heterogeneous versus homogenous 
distribution of VEGF, we can actually look into the activation difference between different 
heterogeneous distributions. The results from this type of study can greatly impact the 
development of the implant industry. It has been known that the roughness of the surface, the 
presentation of bio-signals on implants can greatly affect therapeutic outcomes. It will be even 
more interesting to take the distribution effects of bio-signals into consideration. 
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